Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f3cb:0:b0:441:282b:bd with SMTP id g11csp1047345wrp; Thu, 23 Apr 2026 11:52:19 -0700 (PDT) X-Received: by 2002:a05:622a:4cc5:b0:50f:bb01:9867 with SMTP id d75a77b69052e-50fbb019c74mr157191681cf.25.1776970338939; Thu, 23 Apr 2026 11:52:18 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1776970338; cv=none; d=google.com; s=arc-20240605; b=Zgmn8SIOtrOF3hX+EKOFOhtkCHzTBg3yB/zjdMkZJpZNYL0sciTiQwTXXnYFVM8TrA Fkjp08jMafIjvGZa7t99AGg9MC58j5ouA1wqNGbEkk9M1uo03me4Pp/b3yPNr5QDg9hZ TKIodbpyRA3f93vYlTHS9BD62KOJEWBPXFm/KSMzXliv9D7poVRC3hTY7dzvd7UgKWBj wj6GvGpxf50IyLf/nZFXHh1ZSFoB0Dxptni33pLJFUvXMMBtSHdxCYMOW4i6WZcW2E9R z4kCIZY/KzAvWuSWpy+8vCaQpQRFoUNh6KL4abAp7yzD9vewiIcqopMhqf707vMIjQ9Q yjkQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=LRuhQiLouhJK0VAk8js+8+FPLdhONlCHI3CvjUWXS1k=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=QCR3SIhkZooZZ0btKVzQ4bt+84ampv8VCXx6Va3iqqlhf5xFiKknv/0RTAW40hdvz8 6D8HHUXU2rKpkwYpLKlFB2hGSmnHVlNaPAPqGnJb6neV3rN4N3hvGkM0XAsj/0fMgrkA qKTRZxv1roR0vBhNpjsAgN07VtPuUOwk/74c/sZ/dkkc3BrZNWnHrQSn4pSmoPjtWCch yj2bYLYWQoiv0BEvfCb1CP2x2X3+jJxoPuCB94BIC9GcEKA2pTcA/iCyMtuIUr5hnGKo ms0bWAt7iIeXvR5ZIT73SHr63l2NFMauWBcPcjQA5pOOPfsO40OmhTHkNHGH7i4cuQMD DKQA==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d1.substack.com header.s=k1 header.b="il/nOFQ5"; dkim=pass header.i=@mailgun.org header.s=mg header.b=HY1BTUWS; spf=pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 159.112.244.42 as permitted sender) smtp.mailfrom="bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v542.v5375b7fa.use4.send.mailgun.net (v542.v5375b7fa.use4.send.mailgun.net. [159.112.244.42]) by mx.google.com with UTF8SMTPS id d75a77b69052e-50e394e03c8si286151221cf.288.2026.04.23.11.52.18 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 23 Apr 2026 11:52:18 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 159.112.244.42 as permitted sender) client-ip=159.112.244.42; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d1.substack.com header.s=k1 header.b="il/nOFQ5"; dkim=pass header.i=@mailgun.org header.s=mg header.b=HY1BTUWS; spf=pass (google.com: domain of bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com designates 159.112.244.42 as permitted sender) smtp.mailfrom="bounce+30b528.39b08c6-tjphuhs=gmail.com@mg-d1.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d1.substack.com; q=dns/txt; s=k1; t=1776970338; x=1776977538; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=LRuhQiLouhJK0VAk8js+8+FPLdhONlCHI3CvjUWXS1k=; b=il/nOFQ5mkQ+Ihnb4wRy7gOIPp1f9RoLqzqiEhqWRg0HqBRCF8+7YEUzQ8+YVfd5uFsj9+HY44xLFX91r/Mn4H1i3Kf14LdwFeL+glCw1AbUjwwhYuFabUdEdGnlUcBvB7t6LFbgPjTRNBynYYPOwSL7zsRN9NZsL8+IECwhrjE= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1776970338; x=1776977538; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=LRuhQiLouhJK0VAk8js+8+FPLdhONlCHI3CvjUWXS1k=; b=HY1BTUWSr5qk4wNQtefvSC6BmjULc9T4hRa9t6PDpUEDryczJfmKYe/YampQdh8cSSDkItd9EXR7igMbcyxl/X5sze9i24BfwxSY8qJuOQzIRhdRfkh6z1jSmOAkSLxRsO+UcTKe45o28qrSNQTf9uJW9MBTXw6qEmmX/IJwN7Y= X-Mailgun-Sid: WyIxMWU0ZSIsInRqcGh1aHNAZ21haWwuY29tIiwiMzliMDhjNiJd X-Feedback-Id: postmaster@mg-d1.substack.com:post:614a1297c57bbbe25fa40e08:mailgun Received: by 9452a5a9df5805dd32324071e862320e0609f7b5c0b51cf6b2bde3893520058e with HTTP id 69ea6a626ff65889b3858200; Thu, 23 Apr 2026 18:52:18 GMT X-Mailgun-Sending-Ip: 159.112.244.42 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="b737f41e539c0af1dc573c81921fd2fea2b817af5a3444513ab8dad61c6f" Subject: Orforglipron: Does It Work? Yes. Is It Better Than Subq? Not Even Close. From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260423185124.3.124ec936c576c806@mg-d1.substack.com> Date: Thu, 23 Apr 2026 18:51:24 +0000 Feedback-Id: post-195272431:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1776970338419", "is_freemail": "true", "post_audience": "everyone", "post_id": "195272431", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --b737f41e539c0af1dc573c81921fd2fea2b817af5a3444513ab8dad61c6f Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/orforglipro= n-does-it-work-yes-is An honest look at the first oral GLP-1 that actually works =E2=80=94 and wh= ere it actually fits in a field dominated by injectables Let=E2=80=99s have an honest conversation about orforglipron. It=E2=80=99s the headline GLP-1 story of the last eighteen months. The firs= t oral small-molecule GLP-1 agonist to successfully complete Phase 3. Eli L= illy has already submitted it to the FDA for both obesity and type 2 diabet= es. Likely trade name: Foundayo. The marketing engine is about to go into o= verdrive. Here=E2=80=99s the honest take before we dive in. It works. The data is rea= l. The Phase 3 program is rigorous. But subcutaneous administration is alwa= ys going to hit harder =E2=80=94 and that=E2=80=99s not a limitation of orf= orglipron specifically, it=E2=80=99s physics. Bypassing the digestive tract= means better bioavailability, more predictable pharmacokinetics, and stron= ger downstream effects. Always. Orforglipron doesn=E2=80=99t break that rule. It just offers a real option = for people who were never going to consider subq in the first place. This post is going to walk through the data, compare it to the rest of the = field, and land on the honest answer about where orforglipron actually fits= =2E Which is a narrower space than the coverage suggests. As always, this is research and educational content. Not medical advice. The Framing Most Headlines Miss Before we get into the numbers, it=E2=80=99s worth being clear about what o= rforglipron is and isn=E2=80=99t. It is: A legitimate GLP-1 receptor agonist with real Phase 3 efficacy The first oral GLP-1 without the empty-stomach ritual that handicaps oral s= emaglutide A breakthrough in delivery chemistry =E2=80=94 taking something that should= be destroyed by digestion and getting it absorbed orally is genuinely hard A real option for the population that was never going to use injectables It is not: A competitor to tirzepatide, retatrutide, or cagrisema on efficacy Going to replace subq GLP-1s for people seeking maximum weight loss A gimmick =E2=80=94 the science is solid The =E2=80=9Cfuture of GLP-1s=E2=80=9D the way some headlines are framing i= t Here=E2=80=99s the frame I=E2=80=99d encourage you to hold throughout this = piece. Subq GLP-1s will always outperform oral GLP-1s for the same fundamen= tal reasons real food beats supplements. The gut is a hostile environment f= or drug delivery. Every oral molecule fights absorption, degradation, and f= irst-pass metabolism before it reaches circulation. Subcutaneous administra= tion skips all of that. What orforglipron solves is not an efficacy problem. It=E2=80=99s an access= and acceptance problem. That distinction matters. What Orforglipron Actually Is Orforglipron is a once-daily oral GLP-1 receptor agonist. The key distincti= on =E2=80=94 the one that makes this whole story possible =E2=80=94 is that= it=E2=80=99s a small molecule, not a peptide. Why that matters: Semaglutide, tirzepatide, and every other mainstream GLP-1 is a peptide. Pe= ptides are chains of amino acids. Amino acid chains get obliterated by stom= ach acid and digestive enzymes. That=E2=80=99s why most GLP-1s have to be a= dministered subcutaneously =E2=80=94 put them in your stomach and they=E2= =80=99re just expensive protein. Oral semaglutide exists as a workaround, using a penetration enhancer calle= d SNAC to sneak semaglutide across the gastric lining. But it requires empt= y-stomach dosing, a precise amount of water, and a 30-minute wait before fo= od or other medications. The inconvenience is significant, and the absorbed= dose is tiny compared to subq. Orforglipron is a completely different chemical species. It=E2=80=99s a non= -peptide small molecule =E2=80=94 more like a conventional pharmaceutical d= rug than a biologic =E2=80=94 that binds the GLP-1 receptor and triggers th= e same signaling. Because it=E2=80=99s not made of amino acids, it survives= digestion. Take it any time of day, with or without food. No water restric= tions, no waiting period. It was discovered by Chugai Pharmaceutical in Japan and licensed by Lilly i= n 2018. The Phase 3 program is massive =E2=80=94 the ACHIEVE trials for typ= e 2 diabetes enrolled over 6,000 participants across five studies, and the = ATTAIN program for obesity enrolled over 4,500 more. That=E2=80=99s a significant commitment of capital, and it signals that Lil= ly believes this molecule has real commercial legs. The Mechanism: Nothing New, Different Delivery Orforglipron binds the exact same GLP-1 receptor that semaglutide does. Sam= e signaling. Same downstream effects. The novelty is entirely in the chemis= try of how it gets to that receptor, not in what it does once it arrives. GLP-1 signaling accomplishes four things that matter for obesity and diabet= es: It slows gastric emptying. Food stays in your stomach longer, which means y= ou feel full sooner and stay full longer. This is a significant contributor= to reduced caloric intake. It stimulates glucose-dependent insulin release. When blood sugar is elevat= ed, GLP-1 tells the pancreas to release insulin. The =E2=80=9Cglucose-depen= dent=E2=80=9D qualifier is important =E2=80=94 GLP-1 only triggers insulin = release when it=E2=80=99s actually needed, which is why GLP-1 agonists rare= ly cause hypoglycemia on their own. It suppresses glucagon. Glucagon is the hormone that tells the liver to pro= duce glucose. Dialing that signal down reduces hepatic glucose output and h= elps glycemic control. It acts directly on the brain. This is the big one. GLP-1 receptors are exp= ressed throughout appetite-regulating regions of the central nervous system= =2E Activating them reduces hunger, dec= reases cravings, and changes the rewar= d valence of food. This is where most of the weight loss actually comes fro= m. Orforglipron triggers all of this. It=E2=80=99s the same pharmacology as ev= ery other GLP-1 agonist. The engineering achievement is getting that pharma= cology delivered orally at therapeutic levels. The Phase 3 Data Four trials matter most. Let=E2=80=99s walk through them. ATTAIN-1 =E2=80=94 The Obesity Headliner Published in the New England Journal of Medicine in September 2025. The design was straightforward. 3,127 adults with obesity but no diabetes, = randomized to 6 mg, 12 mg, or 36 mg daily orforglipron or placebo. All dose= s titrated up gradually from 1 mg. Duration: 72 weeks, which is the standar= d for modern obesity trials. Results at the highest dose: Average weight loss: 12.4% (27.3 lbs) Placebo: 0.9% (2.2 lbs) 59.6% of participants lost at least 10% of body weight 39.6% lost at least 15% 18.4% lost at least 20% Meaningful improvements in waist circumference, systolic blood pressure, tr= iglycerides, non-HDL cholesterol, and hsCRP (an inflammation marker) Reference: PMID 40960239 ATTAIN-2 =E2=80=94 Obesity Plus Diabetes Same design, different population =E2=80=94 adults with both obesity and ty= pe 2 diabetes. Results at 36 mg: Weight loss: 10.5% (22.9 lbs) A1C reduction: 1.3% to 1.8% across doses 75% of participants on the highest dose achieved A1C =E2=89=A46.5%, which i= s at or below the diabetes diagnostic threshold hsCRP reduced by 50.6% at the highest dose Note that weight loss is consistently lower in diabetic populations across = all GLP-1 trials =E2=80=94 this isn=E2=80=99t specific to orforglipron. It= =E2=80=99s a phenomenon you see with semaglutide, tirzepatide, and every ot= her agent in the class. ACHIEVE-3 =E2=80=94 The One Head-to-Head That Exists This is the most important trial for context, because it=E2=80=99s the only= direct comparison between orforglipron and the existing oral GLP-1 option. 1,698 adults with type 2 diabetes on metformin were randomized to orforglip= ron (12 mg or 36 mg) or oral semaglutide (7 mg or 14 mg) for 52 weeks. At the highest doses =E2=80=94 orforglipron 36 mg versus oral semaglutide 1= 4 mg: Weight loss: 9.2% vs 5.3% Nearly three times as many participants reached near-normal blood sugar on = orforglipron Orforglipron delivered 73.6% greater relative weight loss Orforglipron beat oral semaglutide decisively on both endpoints. If oral GL= P-1 is the category you=E2=80=99re evaluating, orforglipron is the clear wi= nner within that category. ATTAIN-MAINTAIN =E2=80=94 The Step-Down Study Released December 2025. This one answers a real-world question: can orforgl= ipron maintain weight loss after somebody tapers off a subq GLP-1? Participants from the earlier SURMOUNT-5 study who had been on maximum tole= rated Wegovy or Zepbound for 72 weeks were re-randomized to orforglipron or= placebo for an additional 52 weeks. Results: Orforglipron met the primary and all key secondary endpoints Superior weight maintenance compared to placebo Suggests orforglipron can function as a step-down or maintenance option aft= er injectable therapy This is a legitimately useful indication. The transition off subq GLP-1s ha= s been a practical problem for patients and clinicians alike =E2=80=94 weig= ht regain is common. Having a lower-intensity oral option to hold the losse= s is genuinely valuable. Side Effects: Same Class, Same Profile The adverse event profile is consistent with every other GLP-1 =E2=80=94 GI= -dominant, mostly mild to moderate, worst during dose titration. From ATTAIN-1 at the 36 mg dose: Nausea: 33.7% (vs 10.4% placebo) Constipation: 25.4% (vs 9.3%) Diarrhea: 23.1% (vs 9.6%) Vomiting: 24.0% (vs 3.5%) Dyspepsia: 14.1% (vs 5.0%) Discontinuation specifically due to adverse events scaled with dose: 5.1% a= t 6 mg, 7.7% at 12 mg, 10.3% at 36 mg, versus 2.6% on placebo. Interesting footnote =E2=80=94 total study dropout was actually higher on p= lacebo than on any active dose. Nearly 30% of placebo participants left the= study versus 22-24% on orforglipron. The most likely explanation: people o= n placebo weren=E2=80=99t seeing results and lost motivation to continue. The Honest Comparison: Why Subq Wins This is the section the marketing narrative doesn=E2=80=99t want you to thi= nk about. Here=E2=80=99s the approximate peak-dose weight loss across the modern GLP-= 1 field: Retatrutide 12 mg (subq, weekly): ~28.7% Cagrisema (subq, weekly): ~22.7% Tirzepatide 15 mg (subq, weekly): ~20.9% Semaglutide 2.4 mg (subq, weekly): ~14.9% Orforglipron 36 mg (oral, daily): ~12.4% Oral semaglutide 14 mg: ~5.3% Orforglipron sits at the bottom of the new-generation efficacy ladder. Not = by a little. By a lot. Let=E2=80=99s walk through each comparison honestly. Versus Subq Semaglutide (Wegovy/Ozempic) Subq semaglutide delivers roughly 14.9% weight loss in non-diabetic obesity= =2E Orforglipron delivers 12.4%. Tha= t=E2=80=99s a 2.5 percentage point gap in= favor of subq. Orforglipron holds up reasonably well here. This is the closest comparison = in the entire field. But it still loses to the oldest subq GLP-1 in the mod= ern class =E2=80=94 and that=E2=80=99s with orforglipron at its highest tes= ted dose against semaglutide at its standard dose. One caveat worth noting: a recent indirect comparison (the ORION analysis) = using OASIS-4 data suggested that oral semaglutide at the newer 25 mg dose = may actually outperform orforglipron in non-diabetic populations. Indirect = comparison, not head-to-head, so take it with appropriate skepticism. But i= t=E2=80=99s worth watching. Versus Tirzepatide (Mounjaro/Zepbound) Subq tirzepatide at 15 mg delivers roughly 20.9% weight loss. Orforglipron = 36 mg delivers 12.4%. That=E2=80=99s an eight percentage point gap. Eight percentage points is enormous. On a 250-pound baseline, that=E2=80=99= s the difference between losing 31 pounds and losing 52 pounds. Tirzepatide= is the current efficacy leader among FDA-approved options, and if someone = can tolerate subq administration and is seeking maximum results, there is n= o serious comparison to be made with orforglipron. Versus Retatrutide (Triple Agonist) This is where the gap becomes absurd. Subq retatrutide at 12 mg delivered 2= 8.7% weight loss at 68 weeks in TRIUMPH-4. Break that down further: 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% 23.7% achieved at least 35% Orforglipron 36 mg: 12.4%. Retatrutide is in a different universe =E2=80=94 roughly 2.3x the efficacy = at the same time horizon. It=E2=80=99s still investigational and won=E2=80= =99t hit the market until 2026 or 2027, but when it does, it=E2=80=99s goin= g to reset expectations for what GLP-class therapy can achieve. One thing worth flagging on the retatrutide side: a new dysesthesia signal = emerged in TRIUMPH-4 (abnormal skin sensations like tingling) that wasn=E2= =80=99t seen in the Phase 2 data. Discontinuation at 12 mg hit 18.2%, notab= ly higher than with orforglipron or tirzepatide. Part of this was attribute= d to =E2=80=9Cperceived excessive weight loss=E2=80=9D in lower-BMI partici= pants, which is its own interesting signal. Worth watching as more Phase 3 = data reads out through 2026. Versus Cagrisema (Cagrilintide + Semaglutide) Novo Nordisk=E2=80=99s entry in the dual-agonist space combines a GLP-1 (se= maglutide) with an amylin analog (cagrilintide). Subq, once-weekly. Cagrisema delivered 22.7% weight loss in REDEFINE 1 under the full-adherenc= e estimand. That roughly doubles orforglipron=E2=80=99s efficacy. Worth noting: REDEFINE 4, the head-to-head against tirzepatide, failed to s= how noninferiority. So cagrisema doesn=E2=80=99t displace tirz at the top o= f the efficacy hierarchy. But it absolutely demolishes orforglipron. So Who Is Orforglipron Actually For This is the real question, and the honest answer is narrower than the marke= ting will suggest. It=E2=80=99s a legitimate option for: The single largest population is people who won=E2=80=99t use subq, period.= Needle aversion is real and prevalent. A significant portion of patients w= ho would otherwise benefit from GLP-1 therapy refuse it outright because of= the self-administration requirement. For that population, getting 12% weig= ht loss through a pill is infinitely better than getting 0% because they wo= n=E2=80=99t inject. This is not a small group. Beyond that, orforglipron is reasonable for: Early intervention or less extreme cases where 12-13% weight loss is clinic= ally sufficient Step-down maintenance after subq therapy =E2=80=94 the ATTAIN-MAINTAIN data= supports this specifically Global access populations, particularly in regions where cold-chain storage= and injectable distribution are infrastructure problems. Small-molecule or= al drugs are dramatically easier to distribute than peptide injectables Type 2 diabetes management when oral dosing is strongly preferred =E2=80=94= the ACHIEVE data is solid on glycemic control It is not the right choice for: Anyone who can tolerate subq administration and is seeking maximum weight l= oss Patients with severe obesity who genuinely need 20%+ reduction to reach cli= nical targets Anyone choosing between orforglipron and tirzepatide, retatrutide, or cagri= sema purely on efficacy What We Still Don=E2=80=99t Know The Phase 3 package is robust, but there are genuine unknowns: Long-term cardiovascular outcomes data is still pending (the trial is ongoi= ng) Real-world adherence outside controlled trial settings Head-to-head data versus tirzepatide (doesn=E2=80=99t exist and likely neve= r will) Head-to-head versus subq semaglutide for obesity specifically (doesn=E2=80= =99t exist) How efficacy holds past 72 weeks =E2=80=94 the known treatment horizon The Bottom Line Orforglipron is not a gimmick. The science is legitimate. The Phase 3 data = is rigorous. It=E2=80=99s going to help a real population that would never = otherwise benefit from GLP-1 therapy. That is genuinely valuable, and I don= =E2=80=99t want any of the honest framing above to obscure that point. But let=E2=80=99s call it what it is. Orforglipron is the entry-level moder= n GLP-1. It trades efficacy for oral convenience. For people averse to subc= utaneous administration, that tradeoff makes sense and the oral option is b= etter than nothing. For everyone else, subq is going to outperform it =E2= =80=94 often by enormous margins. The marketing is going to frame this as =E2=80=9CGLP-1s for everyone.=E2=80= =9D The reality is it=E2=80=99s a real option for a specific slice of the p= opulation. That slice is meaningful. It=E2=80=99s just not the whole market= =2E If you=E2=80=99re comfortable with subq administration and seeking maximum = results, the tirzepatide, retatrutide, and cagrisema tier is where the acti= on is. If oral is the only pathway you=E2=80=99ll accept, orforglipron is a= genuine option =E2=80=94 and a meaningfully better one than any oral GLP-1= that came before it. Just don=E2=80=99t confuse what it is with what it isn=E2=80=99t. Key References Wharton S, et al. Orforglipron for Obesity (ATTAIN-1). N Engl J Med. 2025;3= 93(18). PMID 40960239 Rosenstock J, et al. Orforglipron in early type 2 diabetes (ACHIEVE-1). N E= ngl J Med. 2025;393:1065-1076 Horn DB, et al. Orforglipron in T2D with obesity (ATTAIN-2). Lancet. 2025 Novo Nordisk. REDEFINE 1 =E2=80=94 Cagrilintide plus Semaglutide (CagriSema= ). N Engl J Med. 2025 Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity = (SURMOUNT-1). N Engl J Med. 2022 Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Ob= esity (STEP 1). N Engl J Med. 2021 Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesi= ty =E2=80=94 A Phase 2 Trial. N Engl J Med. 2023 Eli Lilly press releases: TRIUMPH-4 (Dec 2025), ATTAIN-MAINTAIN (Dec 2025),= ATTAIN-2 (Aug 2025), ACHIEVE-3 (Sept 2025) This post is for research and educational purposes only. Orforglipron is no= t currently FDA approved. Any decisions about GLP-1 therapy should involve = qualified medical professionals. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOVEkzTWpRek1Td2lhV0YwSWpveE56YzJPV= GN3TXpNNExDSmxlSEFpT2pFNE1EZzFNRFl6TXpnc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LndOZ1FON2Q0c1MxVjFHWENkc2ZJRVVyZkt= ValBqUWJVNGd5SUh4SDByT28iLCJwIjoxOTUyNzI0MzEsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc2OTcwMzM4LCJleHAiOjIwOTI1NDYzMzgsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.weLgFxEswzmC40eiFDorPw4rvIXfjyl9qA_vL6d= j30w? --b737f41e539c0af1dc573c81921fd2fea2b817af5a3444513ab8dad61c6f Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = Orforglipron: Does It Work? Yes. Is It Better Than Subq? Not Even Close.</t= itle><style> @media (max-width: 1024px) { .typography .pullquote-align-left, .typography.editor .pullquote-align-left, .typography .pullquote-align-right, .typography.editor .pullquote-align-right, .typography .pullquote-align-wide, .typography.editor .pullquote-align-wide, .typography .pullquote-align-center, .typography.editor .pullquote-align-center { float: none; margin: 0 auto; width: 100%; max-width: 100%; } } @media all and (-ms-high-contrast: none), (-ms-high-contrast: active) { .typography .markup table.image-wrapper img, .typography.editor .markup table.image-wrapper img, .typography .markup table.kindle-wrapper img, .typography.editor .markup table.kindle-wrapper img { max-width: 550px; } } @media (min-width: 1024px) { .typography:not(:has(#toc)) .captioned-image-container figure:has(> a.ima= ge2-offset-left), .typography.editor:not(:has(#toc)) .captioned-image-container figure:has(= > a.image2-offset-left) { margin-left: var(--image-offset-margin); } .typography:not(:has(#toc)) .captioned-image-container figure:has(> a.ima= ge2-offset-right), .typography.editor:not(:has(#toc)) .captioned-image-container figure:has(= > a.image2-offset-right) { margin-right: var(--image-offset-margin); } } @media (min-width: 1300px) { .typography .captioned-image-container figure:has(> a.image2-offset-left)= , .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-left) { margin-left: var(--image-offset-margin); } .typography .captioned-image-container figure:has(> a.image2-offset-right= ), .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-right) { margin-right: var(--image-offset-margin); } } @media (max-width: 1024px) { .typography, .typography.editor { /* Disable offset on mobile/tablet */ } .typography .captioned-image-container figure:has(> a.image2-align-left), .typography.editor .captioned-image-container figure:has(> a.image2-align= -left), .typography .captioned-image-container figure:has(> a.image2-align-right)= , .typography.editor .captioned-image-container figure:has(> a.image2-align= -right) { float: none; margin: 1em auto; max-width: 100%; width: auto; padding: 0; } .typography .captioned-image-container figure:has(> a.image2-align-left.t= hefp), .typography.editor .captioned-image-container figure:has(> a.image2-align= -left.thefp), .typography .captioned-image-container figure:has(> a.image2-align-right.= thefp), .typography.editor .captioned-image-container figure:has(> a.image2-align= -right.thefp) { margin: 1em auto; } .typography .captioned-image-container figure:has(> a.image2-offset-left)= , .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-left), .typography .captioned-image-container figure:has(> a.image2-offset-right= ), .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-right) { margin: 1em auto; } .typography .captioned-image-container figure:has(> a.image2-align-left) = =2Eimage2-inset, .typography.editor .captioned-image-container figure:has(> a.image2-align= -left) .image2-inset, .typography .captioned-image-container figure:has(> a.image2-align-right)= .image2-inset, .typography.editor .captioned-image-container figure:has(> a.image2-align= -right) .image2-inset { display: block; justify-content: initial; } } @media (max-width: 768px) { .typography .markup div.sponsorship-campaign-embed, .typography.editor .markup div.sponsorship-campaign-embed { margin-top: 24px; margin-bottom: 24px; } .typography .markup div.sponsorship-campaign-embed:first-child, .typography.editor .markup div.sponsorship-campaign-embed:first-child { margin-top: 0px; } } @media screen and (max-width: 650px) { .typography .markup div.youtube-overlay, .typography.editor .markup div.youtube-overlay, .typography .markup div.vimeo-overlay, .typography.editor .markup div.vimeo-overlay { display: none !important; } } @media screen and (max-width: 370px) { .typography .markup div.tiktok-wrap, .typography.editor .markup div.tiktok-wrap { width: calc(95vw - 32px); height: calc((95vw - 32px - 2px) / 0.485714); } } @media screen and (max-width: 650px) { .typography .markup div.embedded-publication-wrap .embedded-publication.s= how-subscribe, .typography.editor .markup div.embedded-publication-wrap .embedded-public= ation.show-subscribe { padding: 24px; } } @media screen and (max-width: 650px) { .typography .markup div.subscription-widget-wrap .subscription-widget.sho= w-subscribe, .typography.editor .markup div.subscription-widget-wrap .subscription-wid= get.show-subscribe, .typography .markup div.subscription-widget-wrap-editor .subscription-wid= get.show-subscribe, .typography.editor .markup div.subscription-widget-wrap-editor .subscript= ion-widget.show-subscribe, .typography .markup div.captioned-button-wrap .subscription-widget.show-s= ubscribe, .typography.editor .markup div.captioned-button-wrap .subscription-widget= =2Eshow-subscribe { padding: 0px 24px; } } @media screen and (max-width: 650px) { .typography .markup div.subscription-widget-wrap .subscription-widget.sho= w-subscribe .subscription-widget-subscribe .button, .typography.editor .markup div.subscription-widget-wrap .subscription-wid= get.show-subscribe .subscription-widget-subscribe .button, .typography .markup div.subscription-widget-wrap-editor .subscription-wid= get.show-subscribe .subscription-widget-subscribe .button, .typography.editor .markup div.subscription-widget-wrap-editor .subscript= ion-widget.show-subscribe .subscription-widget-subscribe .button, .typography .markup div.captioned-button-wrap .subscription-widget.show-s= ubscribe .subscription-widget-subscribe .button, .typography.editor .markup div.captioned-button-wrap .subscription-widget= =2Eshow-subscribe .subscription-widget-subscribe .button { padding: 10px 12px; min-width: 110px; } } @media (max-width: 650px) { .typography .markup .twitter-embed, .typography.editor .markup .twitter-embed, .typography .markup .tweet, .typography.editor .markup .tweet { padding: 12px; } } @media (max-width: 650px) { .typography .markup .twitter-embed .tweet-text, .typography.editor .markup .twitter-embed .tweet-text, .typography .markup .tweet .tweet-text, .typography.editor .markup .tweet .tweet-text { font-size: 14px; line-height: 20px; } } @media (max-width: 650px) { .typography .markup .twitter-embed .tweet-photos-container.two, .typography.editor .markup .twitter-embed .tweet-photos-container.two, .typography .markup .tweet .tweet-photos-container.two, .typography.editor .markup .tweet .tweet-photos-container.two, .typography .markup .twitter-embed .tweet-photos-container.three, .typography.editor .markup .twitter-embed .tweet-photos-container.three, .typography .markup .tweet .tweet-photos-container.three, .typography.editor .markup .tweet .tweet-photos-container.three, .typography .markup .twitter-embed .tweet-photos-container.four, .typography.editor .markup .twitter-embed .tweet-photos-container.four, .typography .markup .tweet .tweet-photos-container.four, .typography.editor .markup .tweet .tweet-photos-container.four { height: 200px; } } @media (max-width: 650px) { .typography .markup .twitter-embed a.expanded-link .expanded-link-img, .typography.editor .markup .twitter-embed a.expanded-link .expanded-link-= img, .typography .markup .tweet a.expanded-link .expanded-link-img, .typography.editor .markup .tweet a.expanded-link .expanded-link-img { max-height: 180px; } } @media (max-width: 650px) { .typography .markup .twitter-embed a.expanded-link .expanded-link-descrip= tion, .typography.editor .markup .twitter-embed a.expanded-link .expanded-link-= description, .typography .markup .tweet a.expanded-link .expanded-link-description, .typography.editor .markup .tweet a.expanded-link .expanded-link-descript= ion { display: none; } } @media screen and (max-width: 650px) { .typography .markup .apple-podcast-container, .typography.editor .markup .apple-podcast-container { width: unset; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed img.install-substack-app-= embed-img, .typography.editor .markup .install-substack-app-embed img.install-substa= ck-app-embed-img { margin: 0 auto 16px auto; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed .install-substack-app-emb= ed-text, .typography.editor .markup .install-substack-app-embed .install-substack-= app-embed-text { margin: 0 0 12px 0; max-width: 100%; width: auto; text-align: center; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed .install-substack-app-emb= ed-link, .typography.editor .markup .install-substack-app-embed .install-substack-= app-embed-link { display: flex; justify-content: center; } } @media screen and (min-width: 481px) { .share-button-container { height: 38px; } } @media screen and (min-width: 481px) { .share-button-container a.comment { height: 38px; line-height: 38px; padding-right: 10px; } } @media screen and (max-width: 480px) { .share-button-container .separator { display: block; margin: 0; height: 8px; border-left: none; } } @media screen and (max-width: 480px) { .share-button-container a.share.first img { padding-left: 0; } } @media screen and (min-width: 481px) { .share-button-container a.mobile { display: none !important; } } @media screen and (min-width: 541px) { .settings-add-pub-modal-wrapper .container .add-recommending-pub-modal-co= ntainer { padding: 36px; height: 680px; } } @media screen and (min-width: 541px) { .settings-add-pub-modal-wrapper .container .add-recommending-pub-modal-co= ntainer .footer { position: absolute; bottom: 36px; margin: 0px; } } @media screen and (max-width: 650px) { .header-anchor-parent { display: none; } } @media screen and (max-width: 768px) { .post { padding: 16px 0 0 0; } } @media screen and (max-width: 650px) { .post .post-header .post-label { margin-top: 8px; } } @media screen and (max-width: 650px) { .post .post-header .meta-author-wrap.alternative-meta .meta-right-column = =2Epost-meta { margin-top: 6px; } } @media screen and (max-width: 650px) { .post .footer-facepile-container { height: 64px; padding: 0 16px; display: flex; align-items: center; justify-content: flex-start; width: 100%; } } @media screen and (max-width: 650px) { .post .post-footer.use-separators { justify-content: center; } } @media screen and (max-width: 650px) { .post .post-footer.next-prev { height: 64px; justify-content: space-between; box-sizing: border-box; } } @media screen and (max-width: 650px) { .post-contributor-footer .post-contributor-bio-table { display: block; } .post-contributor-footer .post-contributor-bio-table-row { display: flex; flex-direction: row; } .post-contributor-footer .post-contributor-bio-userhead-cell, .post-contributor-footer .post-contributor-bio-body-cell { display: block; } .post-contributor-footer .post-contributor-bio-body-cell { flex-grow: 1; } .post-contributor-footer .post-contributor-bio-body-table { display: block; } .post-contributor-footer .post-contributor-bio-body-table-row { display: block; } .post-contributor-footer .post-contributor-bio-copy-cell, .post-contributor-footer .post-contributor-bio-controls-cell { display: block; } .post-contributor-footer .post-contributor-bio-copy-cell { margin: 0 0 16px 0; } .post-contributor-footer .post-contributor-bio-controls-cell { width: auto; } .post-contributor-footer .post-contributor-bio-controls { margin: auto; } .post-contributor-footer .post-contributor-bio-controls .button.primary { width: 100%; } .post-contributor-footer .post-contributor-bio-text { font-size: 14px; } } @media screen and (min-width: 768px) { .post-silhouette { padding: 32px 0; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-title { margin-top: 10.44225025px; height: 120px; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-meta { width: 75%; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-meta.with-byline-image { margin: 20px 0; } } @media screen and (max-width: 650px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item, .post-meta.alternative-meta .post-meta-item { padding-right: 16px; } } @media screen and (max-width: 370px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item, .post-meta.alternative-meta .post-meta-item { font-size: 14px; } } @media screen and (max-width: 650px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item.guest-author-pu= blication, .post-meta.alternative-meta .post-meta-item.guest-author-publication { display: none; } } @media screen and (max-width: 370px) { .post-meta .post-meta-item .post-meta-button { height: 36px !important; /* important to override in-line height style on emails */ } .post-meta .post-meta-item .post-meta-button .meta-button-label { display: none; } .post-meta .post-meta-item .post-meta-button > svg { margin-right: 0; } } @media screen and (max-width: 370px) { .post-meta .post-meta-item { font-size: 12px; } } @media screen and (max-width: 650px) { .post .floating-subscribe-button { bottom: 20px; right: 20px; } } @media (max-width: 1024px) { body .pullquote-align-left, body .pullquote-align-right, body .pullquote-align-wide, body .pullquote-align-center { float: none; margin: 0 auto; width: 100%; max-width: 100%; } } @media all and (-ms-high-contrast: none), (-ms-high-contrast: active) { body .markup table.image-wrapper img, body .markup table.kindle-wrapper img { max-width: 550px; } } @media (min-width: 1024px) { body:not(:has(#toc)) .captioned-image-container figure:has(> a.image2-off= set-left) { margin-left: var(--image-offset-margin); } body:not(:has(#toc)) .captioned-image-container figure:has(> a.image2-off= set-right) { margin-right: var(--image-offset-margin); } } @media (min-width: 1300px) { body .captioned-image-container figure:has(> a.image2-offset-left) { margin-left: var(--image-offset-margin); } body .captioned-image-container figure:has(> a.image2-offset-right) { margin-right: var(--image-offset-margin); } } @media (max-width: 1024px) { body { /* Disable offset on mobile/tablet */ } body .captioned-image-container figure:has(> a.image2-align-left), body .captioned-image-container figure:has(> a.image2-align-right) { float: none; margin: 1em auto; max-width: 100%; width: auto; padding: 0; } body .captioned-image-container figure:has(> a.image2-align-left.thefp), body .captioned-image-container figure:has(> a.image2-align-right.thefp) = { margin: 1em auto; } body .captioned-image-container figure:has(> a.image2-offset-left), body .captioned-image-container figure:has(> a.image2-offset-right) { margin: 1em auto; } body .captioned-image-container figure:has(> a.image2-align-left) .image2= -inset, body .captioned-image-container figure:has(> a.image2-align-right) .image= 2-inset { display: block; justify-content: initial; } } @media (max-width: 768px) { body .markup div.sponsorship-campaign-embed { margin-top: 24px; margin-bottom: 24px; } body .markup div.sponsorship-campaign-embed:first-child { margin-top: 0px; } } @media screen and (max-width: 650px) { body .markup div.youtube-overlay, body .markup div.vimeo-overlay { display: none !important; } } @media screen and (max-width: 370px) { body .markup div.tiktok-wrap { width: calc(95vw - 32px); height: calc((95vw - 32px - 2px) / 0.485714); } } @media screen and (max-width: 650px) { body .markup div.embedded-publication-wrap .embedded-publication.show-sub= scribe { padding: 24px; } } @media screen and (max-width: 650px) { body .markup div.subscription-widget-wrap .subscription-widget.show-subsc= ribe, body .markup div.subscription-widget-wrap-editor .subscription-widget.sho= w-subscribe, body .markup div.captioned-button-wrap .subscription-widget.show-subscrib= e { padding: 0px 24px; } } @media screen and (max-width: 650px) { body .markup div.subscription-widget-wrap .subscription-widget.show-subsc= ribe .subscription-widget-subscribe .button, body .markup div.subscription-widget-wrap-editor .subscription-widget.sho= w-subscribe .subscription-widget-subscribe .button, body .markup div.captioned-button-wrap .subscription-widget.show-subscrib= e .subscription-widget-subscribe .button { padding: 10px 12px; min-width: 110px; } } @media (max-width: 650px) { body .markup .twitter-embed, body .markup .tweet { padding: 12px; } } @media (max-width: 650px) { body .markup .twitter-embed .tweet-text, body .markup .tweet .tweet-text { font-size: 14px; line-height: 20px; } } @media (max-width: 650px) { body .markup .twitter-embed .tweet-photos-container.two, body .markup .tweet .tweet-photos-container.two, body .markup .twitter-embed .tweet-photos-container.three, body .markup .tweet .tweet-photos-container.three, body .markup .twitter-embed .tweet-photos-container.four, body .markup .tweet .tweet-photos-container.four { height: 200px; } } @media (max-width: 650px) { body .markup .twitter-embed a.expanded-link .expanded-link-img, body .markup .tweet a.expanded-link .expanded-link-img { max-height: 180px; } } @media (max-width: 650px) { body .markup .twitter-embed a.expanded-link .expanded-link-description, body .markup .tweet a.expanded-link .expanded-link-description { display: none; } } @media screen and (max-width: 650px) { body .markup .apple-podcast-container { width: unset; } } @media (max-width: 420px) { body .markup .install-substack-app-embed img.install-substack-app-embed-i= mg { margin: 0 auto 16px auto; } } @media (max-width: 420px) { body .markup .install-substack-app-embed .install-substack-app-embed-text= { margin: 0 0 12px 0; max-width: 100%; width: auto; text-align: center; } } @media (max-width: 420px) { body .markup .install-substack-app-embed .install-substack-app-embed-link= { display: flex; justify-content: center; } } @media screen and (min-width: 500px) { body .header a.logo { width: 42px; height: 42px; border-radius: 12px; } } @media screen and (max-width: 420px) { body .subscription-receipt table:first-of-type .subscription-amount .subs= cription-discount { width: 72px !important; } } @media screen and (min-width: 481px) { body .share-button-container { height: auto; } } @media screen and (max-width: 480px) { body .share-button-container .separator { display: block !important; margin: 0 !important; height: 8px !important; border-left: none !important; } } @media screen and (max-width: 650px) { .digest .item .post-meta-item.audience { display: none; } } @media screen and (min-width: 500px) { .digest-publication .logo img { width: 42px; height: 42px; border-radius: 8px; } } @media screen and (max-width: 650px) { .comments-page .container .comment-list .collapsed-reply { margin-left: calc(10 + 32px - 24px); } } @media screen and (max-width: 650px) { .comment > .comment-list { padding-left: 24px; } } @media screen and (max-width: 650px) { .finish-magic-login-modal .modal-content .container { padding: 24px 0; } } @media (max-width: 650px) { .reader2-text-b3 { line-height: 24px; } } @media screen and (max-width: 650px) { .reader2-text-h4 { line-height: 24px; } } @media screen and (min-width: 541px) { .user-profile-modal { padding-left: 12px; padding-right: 12px; } } @media screen and (max-width: 650px) { .subscribe-widget form.form .sideBySideWrap button.rightButton { padding: 10px 12px; } } @media screen and (min-width: 541px) { .pub-icon:hover .logo-hover, .feed-item-icon:hover .logo-hover { display: block; } } @media screen and (max-width: 650px) { .post-ufi.single-full-width-button .post-ufi-button-wrapper { width: 100%; padding: 16px; } .post-ufi.single-full-width-button .post-ufi-button-wrapper:empty { display: none; } .post-ufi.single-full-width-button .post-ufi-button { width: 100%; justify-content: center; } } @media screen and (max-width: 768px) { .file-embed-wrapper { padding: 0; } } @media screen and (max-width: 768px) { .file-embed-wrapper-editor { padding: 0; } } @media screen and (max-width: 768px) { .file-embed-wrapper-editor:active { padding: 0; } } @media only screen and (max-width: 650px) { .file-embed-button.wide, .file-embed-error-button.wide { display: none; } } @media only screen and (min-width: 630px) { .file-embed-button.narrow, .file-embed-error-button.narrow { display: none; } } @media screen and (min-width: 541px) { .audio-player-wrapper .audio-player { min-width: 500px; } } @media screen and (max-width: 650px) { .audio-player-wrapper .audio-player .audio-player-progress { border-left-width: 16px; border-right-width: 16px; } } @media screen and (max-width: 650px) { .audio-player-wrapper .audio-player .audio-player-progress .audio-player-= progress-bar .audio-player-progress-bar-popup { top: -54px; } } @media screen and (max-width: 650px) { .audio-player-wrapper-fancy .audio-player .audio-player-progress { border-left-width: 16px; border-right-width: 16px; } } @media screen and (max-width: 650px) { .audio-player-wrapper-fancy .audio-player .audio-player-progress .audio-p= layer-progress-bar .audio-player-progress-bar-popup { top: -54px; } } @media (min-width: 250px) { .audio-player-wrapper-fancy .audio-player { padding: 32px; } .audio-player-wrapper-fancy .audio-player .btn-group { display: flex; } .audio-player-wrapper-fancy .audio-player .btn-group .button:last-of-type= { display: block; } } @media (min-width: 300px) { .audio-player-wrapper-fancy .audio-player .btn-group { display: block; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } } @media (min-width: 350px) { .audio-player-wrapper-fancy .audio-player .audio-player-substack-logo { display: block; } .audio-player-wrapper-fancy .audio-player .audio-player-title { margin-top: 16px; } .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 15%; width: 15%; display: block; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } .audio-player-wrapper-fancy .audio-player .audio-player-substack-logo { display: block; } } @media (min-width: 350px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 25%; width: 25%; display: block; } .audio-player-wrapper-fancy .audio-player .btn-group { display: flex; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } } @media (min-width: 400px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 40%; width: 40%; } } @media (max-width: 400px) { .audio-player-wrapper-fancy .audio-player .btn-group { margin-top: 12px; } .audio-player-wrapper-fancy .audio-player .btn-group .button { font-size: 13px; padding: 6px 12px; height: auto; margin-top: 10px; } } @media (min-width: 600px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 55%; width: 55%; } } @media (max-width: 650px) { .poll-editor-modal { min-width: calc(100% - 20px); } } @media (max-width: 750px) { .poll-embed .poll-anchor-target .poll-anchor-copy-button { left: 8px; top: 45px; } } @media not all and (min-resolution: 0.001dpcm) { @supports (-webkit-appearance: none) { p a:not(.primary.button), .post p:not(.button-wrapper) a:not(.primary.button), .footnote a.footnote-anchor:not(.primary.button), .thread-head .markup p:not(.button-wrapper) a:not(.primary.button) { color: #ff6719; text-decoration: none; } p a:not(.primary.button):hover, .post p:not(.button-wrapper) a:not(.primary.button):hover, .footnote a.footnote-anchor:not(.primary.button):hover, .thread-head .markup p:not(.button-wrapper) a:not(.primary.button):hove= r { text-decoration: underline; } } }</style></head><body class=3D"email-body" style=3D"font-kerning: auto;--im= age-offset-margin: -120px;"><img src=3D"https://eotrx.substackcdn.com/o/d5a= d4b8bfbe274a1/p.gif?token=3DeyJtIjoiPDIwMjYwNDIzMTg1MTI0LjMuMTI0ZWM5MzZjNTc= 2YzgwNkBtZy1kMS5zdWJzdGFjay5jb20-IiwidSI6MjczNjIyMzk4LCJyIjoidGpwaHVoc0BnbW= FpbC5jb20iLCJkIjoibWctZDEuc3Vic3RhY2suY29tIiwicCI6MTk1MjcyNDMxLCJ0IjoibmV3c= 2xldHRlciIsImEiOiJldmVyeW9uZSIsInMiOjMzNjUzNjcsImMiOiJwb3N0IiwiZiI6dHJ1ZSwi= cG9zaXRpb24iOiJ0b3AiLCJpYXQiOjE3NzY5NzAzMzgsImV4cCI6MTc3OTU2MjMzOCwiaXNzIjo= icHViLTAiLCJzdWIiOiJlbyJ9.4cWusojPfVI5lUB6-5gPXEjRqxc1QWeRS7xkRiB67c4" alt= =3D"" width=3D"1" height=3D"1" border=3D"0" style=3D"height:1px !important;= width:1px !important;border-width:0 !important;margin-top:0 !important;marg= in-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;p= adding-top:0 !important;padding-bottom:0 !important;padding-right:0 !import= ant;padding-left:0 !important;"/><div class=3D"preview" style=3D"display:no= ne;font-size:1px;color:#333333;line-height:1px;max-height:0px;max-width:0px= ;opacity:0;overflow:hidden;">An honest look at the first oral GLP-1 that ac= tually works — and where it actually fits in a field dominated by inj= ectables</div><div class=3D"preview" style=3D"display:none;font-size:1px;co= lor:#333333;line-height:1px;max-height:0px;max-width:0px;opacity:0;overflow= :hidden;">͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­</div><table cl= ass=3D"email-body-container" role=3D"presentation" width=3D"100%" border=3D= "0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td></td><td class=3D"co= ntent" width=3D"550"></td><td></td></tr><tr><td></td><td class=3D"content" = width=3D"550" align=3D"left"><div style=3D"font-size: 16px;line-height: 26p= x;max-width: 550px;width: 100%;margin: 0 auto;overflow-wrap: break-word;"><= table role=3D"presentation" width=3D"100%" border=3D"0" cellspacing=3D"0" c= ellpadding=3D"0"><tbody><tr><td align=3D"right" style=3D"height:20px;"><tab= le role=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cell= padding=3D"0"><tbody><tr><td style=3D"vertical-align:middle;"><span class= =3D"pencraft pc-reset reset-IxiVJZ tw-font-body tw-text-ssm tw-text-substac= k-secondary" style=3D"font-family: SF Pro Text, -apple-system, system-ui, B= linkMacSystemFont, Inter, Segoe UI, Roboto, Helvetica, Arial, sans-serif, A= pple Color Emoji, Segoe UI Emoji, Segoe UI Symbol;font-size: 13px;color: un= set;list-style: none;text-decoration: unset;margin: 0;"><div class=3D"pencr= aft pc-reset align-right-VJbKw5 size-12-mmZ61m reset-IxiVJZ" style=3D"list-= style: none;color: unset;text-align: right;font-size: 12px;line-height: 16p= x;text-decoration: unset;margin: 0;"><span class=3D"pencraft pc-reset reset= -IxiVJZ" translated=3D"" style=3D"list-style: none;color: unset;text-decora= tion: unset;margin: 0;">Forwarded this email? <a class=3D"pencraft pc-reset= decoration-underline-ClTkYc reset-IxiVJZ" href=3D"https://substack.com/red= irect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vc3Vic2NyaWJlP3V= 0bV9zb3VyY2U9ZW1haWwmdXRtX2NhbXBhaWduPWVtYWlsLXN1YnNjcmliZSZyPTRpd29lNiZuZX= h0PWh0dHBzJTNBJTJGJTJGZGVyZWtwcnVza2kuc3Vic3RhY2suY29tJTJGcCUyRm9yZm9yZ2xpc= HJvbi1kb2VzLWl0LXdvcmsteWVzLWlzIiwicCI6MTk1MjcyNDMxLCJzIjozMzY1MzY3LCJmIjp0= cnVlLCJ1IjoyNzM2MjIzOTgsImlhdCI6MTc3Njk3MDMzOCwiZXhwIjoyMDkyNTQ2MzM4LCJpc3M= iOiJwdWItMCIsInN1YiI6ImxpbmstcmVkaXJlY3QifQ.ob0jHvRu1kddVNLDRw1WCjOJzUN6oKn= 5FHvZ-_lo-hI?" style=3D"list-style: none;color: unset;text-decoration: unse= t;margin: 0;-webkit-text-decoration-line: underline;text-decoration-line: u= nderline;">Subscribe here</a> for more</span></div></span></td></tr></tbody= ></table></td></tr></tbody></table><div class=3D"post typography" dir=3D"au= to" style=3D"--image-offset-margin: -120px;padding: 32px 0 0 0;font-size: 1= 6px;line-height: 26px;"><div class=3D"post-header" role=3D"region" aria-lab= el=3D"Post header" style=3D"font-size: 16px;line-height: 26px;"><h1 class= =3D"post-title published title-X77sOw" dir=3D"auto" style=3D"direction: aut= o;text-align: start;unicode-bidi: isolate;color: rgb(54,55,55);font-family:= 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,BlinkMacSy= stemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','= Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing:= antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: optim= izelegibility;-moz-appearance: optimizelegibility;appearance: optimizelegib= ility;margin: 0;line-height: 36px;font-size: 32px;"><a href=3D"https://subs= tack.com/app-link/post?publication_id=3D3365367&post_id=3D195272431&utm_sou= rce=3Dpost-email-title&utm_campaign=3Demail-post-title&isFreemail=3Dtrue&r= =3D4iwoe6&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NTI3MjQzMSwia= WF0IjoxNzc2OTcwMzM4LCJleHAiOjE3Nzk1NjIzMzgsImlzcyI6InB1Yi0zMzY1MzY3Iiwic3Vi= IjoicG9zdC1yZWFjdGlvbiJ9.4bH2Idg-KfvdHXtYQwn-UDDtwJ8AghK1X9l5yvGpu5Q" style= =3D"color: rgb(54,55,55);text-decoration: none;">Orforglipron: Does It Work= ? Yes. Is It Better Than Subq? Not Even Close.</a></h1><table class=3D"post= -meta" role=3D"presentation" width=3D"100%" border=3D"0" cellspacing=3D"0" = cellpadding=3D"0" style=3D"margin: 1em 0;height: 20px;align-items: center;"= ><tbody><tr><td><table role=3D"presentation" width=3D"auto" border=3D"0" ce= llspacing=3D"0" cellpadding=3D"0"><tbody><tr><td><table role=3D"presentatio= n" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><= tr><td style=3D"vertical-align:middle;"><div class=3D"pencraft pc-reset col= or-primary-zABazT line-height-20-t4M0El font-meta-MWBumP size-11-NuY2Zx wei= ght-medium-fw81nC transform-uppercase-yKDgcq reset-IxiVJZ meta-EgzBVA custo= m-css-email-post-author" style=3D"list-style: none;font-size: 11px;line-hei= ght: 20px;text-decoration: unset;color: rgb(54,55,55);margin: 0;font-family= : 'SF Compact',-apple-system,system-ui,-apple-system,BlinkMacSystemFont,'Se= goe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emo= ji','Segoe UI Symbol';font-weight: 500;text-transform: uppercase;letter-spa= cing: .2px;"><a class=3D"pencraft pc-reset color-primary-zABazT line-height= -20-t4M0El font-meta-MWBumP size-11-NuY2Zx weight-medium-fw81nC transform-u= ppercase-yKDgcq reset-IxiVJZ meta-EgzBVA" style=3D"list-style: none;color: = rgb(54,55,55);margin: 0;font-size: 11px;line-height: 20px;font-family: 'SF = Compact',-apple-system,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI= ',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','S= egoe UI Symbol';font-weight: 500;text-transform: uppercase;letter-spacing: = =2E2px;text-decoration: none" href=3D"ht= tps://substack.com/@dereksresearchrad= ar">Derek</a></div></td></tr></tbody></table></td></tr><tr><td><table role= =3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding= =3D"0"><tbody><tr><td style=3D"vertical-align:middle;"><div class=3D"pencra= ft pc-reset color-secondary-ls1g8s line-height-20-t4M0El font-meta-MWBumP s= ize-11-NuY2Zx weight-medium-fw81nC transform-uppercase-yKDgcq reset-IxiVJZ = meta-EgzBVA" style=3D"list-style: none;font-size: 11px;line-height: 20px;te= xt-decoration: unset;color: rgb(119,119,119);margin: 0;font-family: 'SF Com= pact',-apple-system,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',R= oboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Sego= e UI Symbol';font-weight: 500;text-transform: uppercase;letter-spacing: .2p= x;"><time datetime=3D"2026-04-23T18:51:24.776Z">Apr 23</time></div></td></t= r></tbody></table></td></tr></tbody></table></td><td align=3D"right"><table= role=3D"presentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpa= dding=3D"0"><tbody><tr><td style=3D"vertical-align:middle;"><a href=3D"http= s://substack.com/@dereksresearchradar"><img class=3D"custom-css-email-avata= r avatar-QIQ5yR" src=3D"https://substackcdn.com/image/fetch/$s_!27SK!,f_aut= o,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.ama= zonaws.com%2Fpublic%2Fimages%2Ff07a8bac-9f53-43a0-af70-e96356c0f3f3_500x500= =2Epng" style=3D"box-sizing: border-box;= max-width: 550px;border: none;vertica= l-align: middle;width: 40px;height: 40px;min-width: 40px;min-height: 40px;o= bject-fit: cover;margin: 0px;display: inline;border-radius: 50%" width=3D"4= 0" height=3D"40"></a></td></tr></tbody></table></td></tr></tbody></table><t= able class=3D"email-ufi-2-top" role=3D"presentation" width=3D"100%" border= =3D"0" cellspacing=3D"0" cellpadding=3D"0" style=3D"border-top: 1px solid r= gb(0,0,0,.1);border-bottom: 1px solid rgb(0,0,0,.1);min-width: 100%;"><tbod= y><tr height=3D"16"><td height=3D"16" style=3D"font-size:0px;line-height:0;= "> </td></tr><tr><td><table role=3D"presentation" width=3D"100%" borde= r=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td><table role=3D"p= resentation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0= "><tbody><tr><td style=3D"vertical-align:middle;"><table role=3D"presentati= on" width=3D"38" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><t= r><td align=3D"center"><a class=3D"email-icon-button" href=3D"https://subst= ack.com/app-link/post?publication_id=3D3365367&post_id=3D195272431&utm_sour= ce=3Dsubstack&isFreemail=3Dtrue&submitLike=3Dtrue&token=3DeyJ1c2VyX2lkIjoyN= zM2MjIzOTgsInBvc3RfaWQiOjE5NTI3MjQzMSwicmVhY3Rpb24iOiLinaQiLCJpYXQiOjE3NzY5= NzAzMzgsImV4cCI6MTc3OTU2MjMzOCwiaXNzIjoicHViLTMzNjUzNjciLCJzdWIiOiJyZWFjdGl= vbiJ9.Ixx_vp2KovknzVd5lllo6I8bGLqg_yOW4LO9GuH6XBY&utm_medium=3Demail&utm_ca= mpaign=3Demail-reaction&r=3D4iwoe6" style=3D"font-family: system-ui,-apple-= system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'App= le Color Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline-block;fo= nt-weight: 500;border: 1px solid rgb(0,0,0,.1);border-radius: 9999px;text-t= ransform: uppercase;font-size: 12px;line-height: 1;padding: 9px 0;text-deco= ration: none;color: rgb(119,119,119);min-width: 38px;box-sizing: border-box= ;width: 38px"><img class=3D"icon" src=3D"https://substackcdn.com/image/fetc= h/$s_!PeVs!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3A%2F= %2Fsubstack.com%2Ficon%2FLucideHeart%3Fv%3D4%26height%3D36%26fill%3Dnone%26= stroke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"18" style=3D= "border: none;vertical-align: middle;max-width: 18px" alt=3D""></a></td></t= r></tbody></table></td><td width=3D"8" style=3D"min-width:8px;"></td><td st= yle=3D"vertical-align:middle;"><table role=3D"presentation" width=3D"38" bo= rder=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"cent= er"><a class=3D"email-icon-button" href=3D"https://substack.com/app-link/po= st?publication_id=3D3365367&post_id=3D195272431&utm_source=3Dsubstack&utm_m= edium=3Demail&isFreemail=3Dtrue&comments=3Dtrue&token=3DeyJ1c2VyX2lkIjoyNzM= 2MjIzOTgsInBvc3RfaWQiOjE5NTI3MjQzMSwiaWF0IjoxNzc2OTcwMzM4LCJleHAiOjE3Nzk1Nj= IzMzgsImlzcyI6InB1Yi0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.4bH2Idg-Kfvd= HXtYQwn-UDDtwJ8AghK1X9l5yvGpu5Q&r=3D4iwoe6&utm_campaign=3Demail-half-magic-= comments&action=3Dpost-comment&utm_source=3Dsubstack&utm_medium=3Demail" st= yle=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',R= oboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Sego= e UI Symbol';display: inline-block;font-weight: 500;border: 1px solid rgb(0= ,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 12px;li= ne-height: 1;padding: 9px 0;text-decoration: none;color: rgb(119,119,119);m= in-width: 38px;box-sizing: border-box;width: 38px"><img class=3D"icon" src= =3D"https://substackcdn.com/image/fetch/$s_!x1tS!,w_36,c_scale,f_png,q_auto= :good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2FLucideCommen= ts%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth= %3D2" width=3D"18" height=3D"18" style=3D"border: none;vertical-align: midd= le;max-width: 18px" alt=3D""></a></td></tr></tbody></table></td><td width= =3D"8" style=3D"min-width:8px;"></td><td style=3D"vertical-align:middle;"><= table role=3D"presentation" width=3D"38" border=3D"0" cellspacing=3D"0" cel= lpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"email-icon-butto= n" href=3D"https://substack.com/app-link/post?publication_id=3D3365367&post= _id=3D195272431&utm_source=3Dsubstack&utm_medium=3Demail&utm_content=3Dshar= e&utm_campaign=3Demail-share&action=3Dshare&triggerShare=3Dtrue&isFreemail= =3Dtrue&r=3D4iwoe6&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaWQiOjE5NTI3= MjQzMSwiaWF0IjoxNzc2OTcwMzM4LCJleHAiOjE3Nzk1NjIzMzgsImlzcyI6InB1Yi0zMzY1MzY= 3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.4bH2Idg-KfvdHXtYQwn-UDDtwJ8AghK1X9l5yvGpu= 5Q" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe= UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji'= ,'Segoe UI Symbol';display: inline-block;font-weight: 500;border: 1px solid= rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 1= 2px;line-height: 1;padding: 9px 0;text-decoration: none;color: rgb(119,119,= 119);min-width: 38px;box-sizing: border-box;width: 38px"><img class=3D"icon= " src=3D"https://substackcdn.com/image/fetch/$s_!_L14!,w_36,c_scale,f_png,q= _auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2FLucideS= hare2%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWi= dth%3D2" width=3D"18" height=3D"18" style=3D"border: none;vertical-align: m= iddle;max-width: 18px" alt=3D""></a></td></tr></tbody></table></td><td widt= h=3D"8" style=3D"min-width:8px;"></td><td style=3D"vertical-align:middle;">= <table role=3D"presentation" width=3D"38" border=3D"0" cellspacing=3D"0" ce= llpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"email-icon-butt= on" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9vcGVuLnN1YnN= 0YWNrLmNvbS9wdWIvZGVyZWtwcnVza2kvcC9vcmZvcmdsaXByb24tZG9lcy1pdC13b3JrLXllcy= 1pcz91dG1fc291cmNlPXN1YnN0YWNrJnV0bV9tZWRpdW09ZW1haWwmdXRtX2NhbXBhaWduPWVtY= WlsLXJlc3RhY2stY29tbWVudCZhY3Rpb249cmVzdGFjay1jb21tZW50JnI9NGl3b2U2JnRva2Vu= PWV5SjFjMlZ5WDJsa0lqb3lOek0yTWpJek9UZ3NJbkJ2YzNSZmFXUWlPakU1TlRJM01qUXpNU3d= pYVdGMElqb3hOemMyT1Rjd016TTRMQ0psZUhBaU9qRTNOemsxTmpJek16Z3NJbWx6Y3lJNkluQj= FZaTB6TXpZMU16WTNJaXdpYzNWaUlqb2ljRzl6ZEMxeVpXRmpkR2x2YmlKOS40YkgySWRnLUtmd= mRIWHRZUXduLVVERHR3SjhBZ2hLMVg5bDV5dkdwdTVRIiwicCI6MTk1MjcyNDMxLCJzIjozMzY1= MzY3LCJmIjp0cnVlLCJ1IjoyNzM2MjIzOTgsImlhdCI6MTc3Njk3MDMzOCwiZXhwIjoyMDkyNTQ= 2MzM4LCJpc3MiOiJwdWItMCIsInN1YiI6ImxpbmstcmVkaXJlY3QifQ.0JUAvDSP9N8SoVGSeRU= F5Ocp8Az_QzO1uVecwen9pNI?&utm_source=3Dsubstack&utm_medium=3Demail" style= =3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Robo= to,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe U= I Symbol';display: inline-block;font-weight: 500;border: 1px solid rgb(0,0,= 0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 12px;line-= height: 1;padding: 9px 0;text-decoration: none;color: rgb(119,119,119);min-= width: 38px;box-sizing: border-box;width: 38px"><img class=3D"icon" src=3D"= https://substackcdn.com/image/fetch/$s_!ubXF!,w_36,c_scale,f_png,q_auto:goo= d,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon%2Fnotes__NoteResta= ckIcon%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeW= idth%3D2%26strokeLinecap%3Dround%26strokeLinejoin%3Dround" width=3D"18" hei= ght=3D"18" alt=3D"" style=3D"max-width: 550px;border: none !important;verti= cal-align: middle;"></a></td></tr></tbody></table></td></tr></tbody></table= ></td><td align=3D"right"><table role=3D"presentation" width=3D"auto" borde= r=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td style=3D"vertica= l-align:middle;"><table role=3D"presentation" width=3D"auto" border=3D"0" c= ellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"center"><a class= =3D"email-button-outline" href=3D"https://open.substack.com/pub/derekpruski= /p/orforglipron-does-it-work-yes-is?utm_source=3Demail&redirect=3Dapp-store= &utm_campaign=3Demail-read-in-app" style=3D"font-family: system-ui,-apple-s= ystem,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Appl= e Color Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline-block;fon= t-weight: 500;border: 1px solid rgb(0,0,0,.1);border-radius: 9999px;text-tr= ansform: uppercase;font-size: 12px;line-height: 12px;padding: 9px 14px;text= -decoration: none;color: rgb(119,119,119);"><div class=3D"email-button-spac= er" style=3D"font-size: 16px;line-height: 26px;display: inline-block;vertic= al-align: middle;max-width: 0;min-height: 18px;"></div><span class=3D"email= -button-text" style=3D"vertical-align: middle;margin-right: 4px">READ IN AP= P</span><img class=3D"icon text-icon" src=3D"https://substackcdn.com/image/= fetch/$s_!ET-_!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3= A%2F%2Fsubstack.com%2Ficon%2FLucideArrowUpRight%3Fv%3D4%26height%3D36%26fil= l%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"1= 8" style=3D"min-width: 18px;min-height: 18px;border: none;vertical-align: m= iddle;margin-right: 0;margin-left: 0;max-width: 18px" alt=3D""></a></td></t= r></tbody></table></td></tr></tbody></table></td></tr></tbody></table></td>= </tr><tr height=3D"16"><td height=3D"16" style=3D"font-size:0px;line-height= :0;"> </td></tr></tbody></table></div></div><div class=3D"post typogra= phy" dir=3D"auto" style=3D"--image-offset-margin: -120px;padding: 32px 0 0 = 0;font-size: 16px;line-height: 26px;"><div class=3D"body markup" dir=3D"aut= o" style=3D"text-align: initial;font-size: 16px;line-height: 26px;width: 10= 0%;word-break: break-word;margin-bottom: 16px;"><h3 class=3D"header-anchor-= post" style=3D"position: relative;font-family: 'SF Pro Display',-apple-syst= em-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,He= lvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Sym= bol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-sm= oothing: antialiased;-webkit-appearance: optimizelegibility;-moz-appearance= : optimizelegibility;appearance: optimizelegibility;margin: 1em 0 0.625em 0= ;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.375em;margin-top: 0;= ">An honest look at the first oral GLP-1 that actually works — and wh= ere it actually fits in a field dominated by injectables</h3><div style=3D"= font-size: 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padding: 0;= height: 1px;background: rgb(0,0,0,.1);border: none;"></div><p style=3D"marg= in: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Let= ’s have an honest conversation about orforglipron.</p><p style=3D"mar= gin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">It= ’s the headline GLP-1 story of the last eighteen months. The first or= al small-molecule GLP-1 agonist to successfully complete Phase 3. Eli Lilly= has already submitted it to the FDA for both obesity and type 2 diabetes. = Likely trade name: Foundayo. The marketing engine is about to go into overd= rive.</p><div class=3D"captioned-image-container-static" style=3D"font-size= : 16px;line-height: 26px;margin: 32px auto;"><figure style=3D"width: 100%;m= argin: 0 auto;"><table class=3D"image-wrapper" width=3D"100%" border=3D"0" = cellspacing=3D"0" cellpadding=3D"0" data-component-name=3D"Image2ToDOMStati= c" style=3D"mso-padding-alt: 1em 0 1.6em;"><tbody><tr><td style=3D"text-ali= gn: center;"></td><td class=3D"content" align=3D"left" width=3D"1456" style= =3D"text-align: center;"><a class=3D"image-link" target=3D"_blank" href=3D"= https://substack.com/redirect/5644b780-4544-441e-9d4e-e70e36dfa947?j=3DeyJ1= IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs" style=3D"posit= ion: relative;flex-direction: column;align-items: center;padding: 0;width: = auto;height: auto;border: none;text-decoration: none;display: block;margin:= 0;"><img class=3D"wide-image" data-attrs=3D"{"src":"https:/= /substack-post-media.s3.amazonaws.com/public/images/596e7343-fe4a-4861-a40f= -2e310fd70094_1536x1024.png","srcNoWatermark":null,"ful= lscreen":null,"imageSize":null,"height":971,"= width":1456,"resizeWidth":null,"bytes":2122003,&qu= ot;alt":null,"title":null,"type":"image/png&q= uot;,"href":null,"belowTheFold":false,"topImage&qu= ot;:true,"internalRedirect":"https://derekpruski.substack.co= m/i/195272431?img=3Dhttps%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpu= blic%2Fimages%2F596e7343-fe4a-4861-a40f-2e310fd70094_1536x1024.png",&q= uot;isProcessing":false,"align":null,"offset":fals= e}" alt=3D"" width=3D"550" height=3D"366.7925824175824" src=3D"https://subs= tackcdn.com/image/fetch/$s_!Hd9l!,w_1100,c_limit,f_auto,q_auto:good,fl_prog= ressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2= Fimages%2F596e7343-fe4a-4861-a40f-2e310fd70094_1536x1024.png" style=3D"bord= er: none !important;vertical-align: middle;display: block;-ms-interpolation= -mode: bicubic;height: auto;margin-bottom: 0;width: auto !important;max-wid= th: 100% !important;margin: 0 auto;"></a></td><td style=3D"text-align: cent= er;"></td></tr></tbody></table></figure></div><p style=3D"margin: 0 0 20px = 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"></p><p style=3D"= margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"= >Here’s the honest take before we dive in. It works. The data is real= =2E The Phase 3 program is rigorous. Bu= t subcutaneous administration is alway= s going to hit harder — and that’s not a limitation of orforgli= pron specifically, it’s physics. Bypassing the digestive tract means = better bioavailability, more predictable pharmacokinetics, and stronger dow= nstream effects. Always.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55= ,55);line-height: 26px;font-size: 16px;">Orforglipron doesn’t break t= hat rule. It just offers a real option for people who were never going to c= onsider subq in the first place.</p><p style=3D"margin: 0 0 20px 0;color: r= gb(54,55,55);line-height: 26px;font-size: 16px;">This post is going to walk= through the data, compare it to the rest of the field, and land on the hon= est answer about where orforglipron actually fits. Which is a narrower spac= e than the coverage suggests.</p><p style=3D"margin: 0 0 20px 0;color: rgb(= 54,55,55);line-height: 26px;font-size: 16px;">As always, this is research a= nd educational content. Not medical advice.</p><div class=3D"subscribe-widg= et is-signed-up" data-component-name=3D"SubscribeWidget" style=3D"margin: 0= 0 1em;direction: ltr;font-size: 16px;line-height: 26px;"><div class=3D"pen= craft pc-reset button-wrapper" style=3D"text-decoration: unset;list-style: = none;font-size: 16px;line-height: 26px;text-align: center;cursor: pointer;b= order-radius: 4px;"><a class=3D"button subscribe-btn primary" href=3D"https= ://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5j= b20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1dG1fY2FtcGFpZ249ZW1haWwtY2hlY2tvdXQ= mbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tpLnN1YnN0YWNrLmNvbSUyRnAlMkZvcmZvcm= dsaXByb24tZG9lcy1pdC13b3JrLXllcy1pcyZyPTRpd29lNiZ0b2tlbj1leUoxYzJWeVgybGtJa= m95TnpNMk1qSXpPVGdzSW1saGRDSTZNVGMzTmprM01ETXpPQ3dpWlhod0lqb3hOemM1TlRZeU16= TTRMQ0pwYzNNaU9pSndkV0l0TXpNMk5UTTJOeUlzSW5OMVlpSTZJbU5vWldOcmIzVjBJbjAuV1d= VVHNHalVyeU1XYkN5bUE3enM4T1Y4dEZGa0VKRXFEaFRueXJkd3JfQSIsInAiOjE5NTI3MjQzMS= wicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMzk4LCJpYXQiOjE3NzY5NzAzMzgsImV4c= CI6MjA5MjU0NjMzOCwiaXNzIjoicHViLTAiLCJzdWIiOiJsaW5rLXJlZGlyZWN0In0.Mua1SAxq= MyMLXNwDukaKuhNgeDj5PDf9dSlwyTePO1o?&utm_medium=3Demail&utm_source=3Dsubscr= ibe-widget&utm_content=3D195272431" style=3D"font-family: system-ui,-apple-= system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'App= le Color Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline-block;bo= x-sizing: border-box;cursor: pointer;border: none;border-radius: 8px;font-s= ize: 14px;line-height: 20px;font-weight: 600;text-align: center;opacity: 1;= outline: none;white-space: nowrap;text-decoration: none !important;margin: = 0 auto;background-color: #FF6719;color: #ffffff !important;padding: 12px 20= px;height: auto;"><span style=3D"color: #ffffff;text-decoration: none;">Upg= rade to paid</span></a></div></div><div style=3D"font-size: 16px;line-heigh= t: 26px;"><hr style=3D"margin: 32px 0;padding: 0;height: 1px;background: rg= b(0,0,0,.1);border: none;"></div><h2 class=3D"header-anchor-post" style=3D"= position: relative;font-family: 'SF Pro Display',-apple-system-headline,sys= tem-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,s= ans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weigh= t: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antial= iased;-webkit-appearance: optimizelegibility;-moz-appearance: optimizelegib= ility;appearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,= 55,55);line-height: 1.16em;font-size: 1.625em;">The Framing Most Headlines = Miss</h2><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 2= 6px;font-size: 16px;">Before we get into the numbers, it’s worth bein= g clear about what orforglipron is and isn’t.</p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong= >It is:</strong></p><ul style=3D"margin-top: 0;padding: 0;"><li style=3D"ma= rgin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,5= 5,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-lef= t: 4px;font-size: 16px;margin: 0;">A legitimate GLP-1 receptor agonist with= real Phase 3 efficacy</p></li><li style=3D"margin: 8px 0 0 32px;mso-specia= l-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margi= n-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin= : 0;">The first oral GLP-1 without the empty-stomach ritual that handicaps = oral semaglutide</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-form= at: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bott= om: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">= A breakthrough in delivery chemistry — taking something that should b= e destroyed by digestion and getting it absorbed orally is genuinely hard</= p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p st= yle=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: = border-box;padding-left: 4px;font-size: 16px;margin: 0;">A real option for = the population that was never going to use injectables</p></li></ul><p styl= e=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 1= 6px;"><strong>It is not:</strong></p><ul style=3D"margin-top: 0;padding: 0;= "><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style= =3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: bor= der-box;padding-left: 4px;font-size: 16px;margin: 0;">A competitor to tirze= patide, retatrutide, or cagrisema on efficacy</p></li><li style=3D"margin: = 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);= line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px= ;font-size: 16px;margin: 0;">Going to replace subq GLP-1s for people seekin= g maximum weight loss</p></li><li style=3D"margin: 8px 0 0 32px;mso-special= -format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin= -bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin:= 0;">A gimmick — the science is solid</p></li><li style=3D"margin: 8p= x 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);li= ne-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;f= ont-size: 16px;margin: 0;">The “future of GLP-1s” the way some = headlines are framing it</p></li></ul><p style=3D"margin: 0 0 20px 0;color:= rgb(54,55,55);line-height: 26px;font-size: 16px;">Here’s the frame I= ’d encourage you to hold throughout this piece. Subq GLP-1s will alwa= ys outperform oral GLP-1s for the same fundamental reasons real food beats = supplements. The gut is a hostile environment for drug delivery. Every oral= molecule fights absorption, degradation, and first-pass metabolism before = it reaches circulation. Subcutaneous administration skips all of that.</p><= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">What orforglipron solves is not an efficacy problem. It’s= an access and acceptance problem. That distinction matters.</p><div style= =3D"font-size: 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padding= : 0;height: 1px;background: rgb(0,0,0,.1);border: none;"></div><h2 class=3D= "header-anchor-post" style=3D"position: relative;font-family: 'SF Pro Displ= ay',-apple-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Sego= e UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji= ','Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-= moz-osx-font-smoothing: antialiased;-webkit-appearance: optimizelegibility;= -moz-appearance: optimizelegibility;appearance: optimizelegibility;margin: = 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.625em= ;">What Orforglipron Actually Is</h2><p style=3D"margin: 0 0 20px 0;color: = rgb(54,55,55);line-height: 26px;font-size: 16px;"><span>Orforglipron is a o= nce-daily oral GLP-1 receptor agonist. The key distinction — the one = that makes this whole story possible — is that it’s a </span><s= trong>small molecule, not a peptide</strong><span>.</span></p><p style=3D"m= argin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">= Why that matters:</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);li= ne-height: 26px;font-size: 16px;">Semaglutide, tirzepatide, and every other= mainstream GLP-1 is a peptide. Peptides are chains of amino acids. Amino a= cid chains get obliterated by stomach acid and digestive enzymes. That̵= 7;s why most GLP-1s have to be administered subcutaneously — put them= in your stomach and they’re just expensive protein.</p><p style=3D"m= argin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">= Oral semaglutide exists as a workaround, using a penetration enhancer calle= d SNAC to sneak semaglutide across the gastric lining. But it requires empt= y-stomach dosing, a precise amount of water, and a 30-minute wait before fo= od or other medications. The inconvenience is significant, and the absorbed= dose is tiny compared to subq.</p><p style=3D"margin: 0 0 20px 0;color: rg= b(54,55,55);line-height: 26px;font-size: 16px;">Orforglipron is a completel= y different chemical species. It’s a non-peptide small molecule ̵= 2; more like a conventional pharmaceutical drug than a biologic — tha= t binds the GLP-1 receptor and triggers the same signaling. Because it̵= 7;s not made of amino acids, it survives digestion. Take it any time of day= , with or without food. No water restrictions, no waiting period.</p><p sty= le=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: = 16px;">It was discovered by Chugai Pharmaceutical in Japan and licensed by = Lilly in 2018. The Phase 3 program is massive — the ACHIEVE trials fo= r type 2 diabetes enrolled over 6,000 participants across five studies, and= the ATTAIN program for obesity enrolled over 4,500 more.</p><p style=3D"ma= rgin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">T= hat’s a significant commitment of capital, and it signals that Lilly = believes this molecule has real commercial legs.</p><div style=3D"font-size= : 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padding: 0;height: 1= px;background: rgb(0,0,0,.1);border: none;"></div><h2 class=3D"header-ancho= r-post" style=3D"position: relative;font-family: 'SF Pro Display',-apple-sy= stem-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,= Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI S= ymbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-= smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz-appearan= ce: optimizelegibility;appearance: optimizelegibility;margin: 1em 0 0.625em= 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.625em;">The Mechan= ism: Nothing New, Different Delivery</h2><p style=3D"margin: 0 0 20px 0;col= or: rgb(54,55,55);line-height: 26px;font-size: 16px;">Orforglipron binds th= e exact same GLP-1 receptor that semaglutide does. Same signaling. Same dow= nstream effects. The novelty is entirely in the chemistry of how it gets to= that receptor, not in what it does once it arrives.</p><p style=3D"margin:= 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">GLP-1 = signaling accomplishes four things that matter for obesity and diabetes:</p= ><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font= -size: 16px;"><strong>It slows gastric emptying.</strong><span> Food stays = in your stomach longer, which means you feel full sooner and stay full long= er. This is a significant contributor to reduced caloric intake.</span></p>= <p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-= size: 16px;"><strong>It stimulates glucose-dependent insulin release.</stro= ng><span> When blood sugar is elevated, GLP-1 tells the pancreas to release= insulin. The “glucose-dependent” qualifier is important —= ; GLP-1 only triggers insulin release when it’s actually needed, whic= h is why GLP-1 agonists rarely cause hypoglycemia on their own.</span></p><= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;"><strong>It suppresses glucagon.</strong><span> Glucagon is the = hormone that tells the liver to produce glucose. Dialing that signal down r= educes hepatic glucose output and helps glycemic control.</span></p><p styl= e=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 1= 6px;"><strong>It acts directly on the brain.</strong><span> This is the big= one. GLP-1 receptors are expressed throughout appetite-regulating regions = of the central nervous system. Activating them reduces hunger, decreases cr= avings, and changes the reward valence of food. This is where most of the w= eight loss actually comes from.</span></p><p style=3D"margin: 0 0 20px 0;co= lor: rgb(54,55,55);line-height: 26px;font-size: 16px;">Orforglipron trigger= s all of this. It’s the same pharmacology as every other GLP-1 agonis= t. The engineering achievement is getting that pharmacology delivered orall= y at therapeutic levels.</p><div style=3D"font-size: 16px;line-height: 26px= ;"><hr style=3D"margin: 32px 0;padding: 0;height: 1px;background: rgb(0,0,0= ,.1);border: none;"></div><h2 class=3D"header-anchor-post" style=3D"positio= n: relative;font-family: 'SF Pro Display',-apple-system-headline,system-ui,= -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-ser= if,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold= ;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-= webkit-appearance: optimizelegibility;-moz-appearance: optimizelegibility;a= ppearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);= line-height: 1.16em;font-size: 1.625em;">The Phase 3 Data</h2><p style=3D"m= argin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">= Four trials matter most. Let’s walk through them.</p><h3 class=3D"hea= der-anchor-post" style=3D"position: relative;font-family: 'SF Pro Display',= -apple-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI= ',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','S= egoe UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-= osx-font-smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz= -appearance: optimizelegibility;appearance: optimizelegibility;margin: 1em = 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.375em;">A= TTAIN-1 — The Obesity Headliner</h3><p style=3D"margin: 0 0 20px 0;co= lor: rgb(54,55,55);line-height: 26px;font-size: 16px;"><span>Published in t= he </span><em>New England Journal of Medicine</em><span> in September 2025.= </span></p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height:= 26px;font-size: 16px;">The design was straightforward. 3,127 adults with o= besity but no diabetes, randomized to 6 mg, 12 mg, or 36 mg daily orforglip= ron or placebo. All doses titrated up gradually from 1 mg. Duration: 72 wee= ks, which is the standard for modern obesity trials.</p><p style=3D"margin:= 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Result= s at the highest dose:</p><ul style=3D"margin-top: 0;padding: 0;"><li style= =3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rg= b(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;paddi= ng-left: 4px;font-size: 16px;margin: 0;"><span>Average weight loss: </span>= <strong>12.4%</strong><span> (27.3 lbs)</span></p></li><li style=3D"margin:= 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55)= ;line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4p= x;font-size: 16px;margin: 0;">Placebo: 0.9% (2.2 lbs)</p></li><li style=3D"= margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54= ,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-l= eft: 4px;font-size: 16px;margin: 0;">59.6% of participants lost at least 10= % of body weight</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-form= at: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bott= om: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">= 39.6% lost at least 15%</p></li><li style=3D"margin: 8px 0 0 32px;mso-speci= al-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;marg= in-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margi= n: 0;">18.4% lost at least 20%</p></li><li style=3D"margin: 8px 0 0 32px;ms= o-special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26= px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16p= x;margin: 0;">Meaningful improvements in waist circumference, systolic bloo= d pressure, triglycerides, non-HDL cholesterol, and hsCRP (an inflammation = marker)</p></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);li= ne-height: 26px;font-size: 16px;">Reference: PMID 40960239</p><h3 class=3D"= header-anchor-post" style=3D"position: relative;font-family: 'SF Pro Displa= y',-apple-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe= UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji'= ,'Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-m= oz-osx-font-smoothing: antialiased;-webkit-appearance: optimizelegibility;-= moz-appearance: optimizelegibility;appearance: optimizelegibility;margin: 1= em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.375em;= ">ATTAIN-2 — Obesity Plus Diabetes</h3><p style=3D"margin: 0 0 20px 0= ;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Same design, diff= erent population — adults with both obesity and type 2 diabetes.</p><= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">Results at 36 mg:</p><ul style=3D"margin-top: 0;padding: 0;"><l= i style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"co= lor: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-bo= x;padding-left: 4px;font-size: 16px;margin: 0;">Weight loss: 10.5% (22.9 lb= s)</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><= p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizi= ng: border-box;padding-left: 4px;font-size: 16px;margin: 0;">A1C reduction:= 1.3% to 1.8% across doses</p></li><li style=3D"margin: 8px 0 0 32px;mso-sp= ecial-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;m= argin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;ma= rgin: 0;">75% of participants on the highest dose achieved A1C ≤6.5%,= which is at or below the diabetes diagnostic threshold</p></li><li style= =3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rg= b(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;paddi= ng-left: 4px;font-size: 16px;margin: 0;">hsCRP reduced by 50.6% at the high= est dose</p></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);l= ine-height: 26px;font-size: 16px;">Note that weight loss is consistently lo= wer in diabetic populations across all GLP-1 trials — this isn’= t specific to orforglipron. It’s a phenomenon you see with semaglutid= e, tirzepatide, and every other agent in the class.</p><h3 class=3D"header-= anchor-post" style=3D"position: relative;font-family: 'SF Pro Display',-app= le-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Ro= boto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe= UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-= font-smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz-app= earance: optimizelegibility;appearance: optimizelegibility;margin: 1em 0 0.= 625em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.375em;">ACHIE= VE-3 — The One Head-to-Head That Exists</h3><p style=3D"margin: 0 0 2= 0px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">This is the = most important trial for context, because it’s the only direct compar= ison between orforglipron and the existing oral GLP-1 option.</p><p style= =3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16= px;">1,698 adults with type 2 diabetes on metformin were randomized to orfo= rglipron (12 mg or 36 mg) or oral semaglutide (7 mg or 14 mg) for 52 weeks.= </p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;f= ont-size: 16px;">At the highest doses — orforglipron 36 mg versus ora= l semaglutide 14 mg:</p><ul style=3D"margin-top: 0;padding: 0;"><li style= =3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rg= b(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;paddi= ng-left: 4px;font-size: 16px;margin: 0;"><span>Weight loss: </span><strong>= 9.2% vs 5.3%</strong></p></li><li style=3D"margin: 8px 0 0 32px;mso-special= -format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin= -bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin:= 0;">Nearly three times as many participants reached near-normal blood suga= r on orforglipron</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-for= mat: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bot= tom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;"= >Orforglipron delivered 73.6% greater relative weight loss</p></li></ul><p = style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-siz= e: 16px;">Orforglipron beat oral semaglutide decisively on both endpoints. = If oral GLP-1 is the category you’re evaluating, orforglipron is the = clear winner within that category.</p><h3 class=3D"header-anchor-post" styl= e=3D"position: relative;font-family: 'SF Pro Display',-apple-system-headlin= e,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Ar= ial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-= weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: a= ntialiased;-webkit-appearance: optimizelegibility;-moz-appearance: optimize= legibility;appearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rg= b(54,55,55);line-height: 1.16em;font-size: 1.375em;">ATTAIN-MAINTAIN —= ; The Step-Down Study</h3><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,5= 5);line-height: 26px;font-size: 16px;">Released December 2025. This one ans= wers a real-world question: can orforglipron maintain weight loss after som= ebody tapers off a subq GLP-1?</p><p style=3D"margin: 0 0 20px 0;color: rgb= (54,55,55);line-height: 26px;font-size: 16px;">Participants from the earlie= r SURMOUNT-5 study who had been on maximum tolerated Wegovy or Zepbound for= 72 weeks were re-randomized to orforglipron or placebo for an additional 5= 2 weeks.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height= : 26px;font-size: 16px;">Results:</p><ul style=3D"margin-top: 0;padding: 0;= "><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style= =3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: bor= der-box;padding-left: 4px;font-size: 16px;margin: 0;">Orforglipron met the = primary and all key secondary endpoints</p></li><li style=3D"margin: 8px 0 = 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-h= eight: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-= size: 16px;margin: 0;">Superior weight maintenance compared to placebo</p><= /li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style= =3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: bor= der-box;padding-left: 4px;font-size: 16px;margin: 0;">Suggests orforglipron= can function as a step-down or maintenance option after injectable therapy= </p></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-heig= ht: 26px;font-size: 16px;">This is a legitimately useful indication. The tr= ansition off subq GLP-1s has been a practical problem for patients and clin= icians alike — weight regain is common. Having a lower-intensity oral= option to hold the losses is genuinely valuable.</p><div style=3D"font-siz= e: 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padding: 0;height: = 1px;background: rgb(0,0,0,.1);border: none;"></div><h2 class=3D"header-anch= or-post" style=3D"position: relative;font-family: 'SF Pro Display',-apple-s= ystem-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto= ,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI = Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font= -smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz-appeara= nce: optimizelegibility;appearance: optimizelegibility;margin: 1em 0 0.625e= m 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.625em;">Side Effe= cts: Same Class, Same Profile</h2><p style=3D"margin: 0 0 20px 0;color: rgb= (54,55,55);line-height: 26px;font-size: 16px;">The adverse event profile is= consistent with every other GLP-1 — GI-dominant, mostly mild to mode= rate, worst during dose titration.</p><p style=3D"margin: 0 0 20px 0;color:= rgb(54,55,55);line-height: 26px;font-size: 16px;">From ATTAIN-1 at the 36 = mg dose:</p><ul style=3D"margin-top: 0;padding: 0;"><li style=3D"margin: 8p= x 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);li= ne-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;f= ont-size: 16px;margin: 0;">Nausea: 33.7% (vs 10.4% placebo)</p></li><li sty= le=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: = rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;pad= ding-left: 4px;font-size: 16px;margin: 0;">Constipation: 25.4% (vs 9.3%)</p= ></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p sty= le=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: b= order-box;padding-left: 4px;font-size: 16px;margin: 0;">Diarrhea: 23.1% (vs= 9.6%)</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet= ;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-= sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">Vomiting: = 24.0% (vs 3.5%)</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-forma= t: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-botto= m: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">D= yspepsia: 14.1% (vs 5.0%)</p></li></ul><p style=3D"margin: 0 0 20px 0;color= : rgb(54,55,55);line-height: 26px;font-size: 16px;">Discontinuation specifi= cally due to adverse events scaled with dose: 5.1% at 6 mg, 7.7% at 12 mg, = 10.3% at 36 mg, versus 2.6% on placebo.</p><p style=3D"margin: 0 0 20px 0;c= olor: rgb(54,55,55);line-height: 26px;font-size: 16px;"><span>Interesting f= ootnote — total study dropout was actually </span><em>higher</em><spa= n> on placebo than on any active dose. Nearly 30% of placebo participants l= eft the study versus 22-24% on orforglipron. The most likely explanation: p= eople on placebo weren’t seeing results and lost motivation to contin= ue.</span></p><div style=3D"font-size: 16px;line-height: 26px;"><hr style= =3D"margin: 32px 0;padding: 0;height: 1px;background: rgb(0,0,0,.1);border:= none;"></div><h2 class=3D"header-anchor-post" style=3D"position: relative;= font-family: 'SF Pro Display',-apple-system-headline,system-ui,-apple-syste= m,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Co= lor Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-fon= t-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appea= rance: optimizelegibility;-moz-appearance: optimizelegibility;appearance: o= ptimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height:= 1.16em;font-size: 1.625em;">The Honest Comparison: Why Subq Wins</h2><p st= yle=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size:= 16px;">This is the section the marketing narrative doesn’t want you = to think about.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line= -height: 26px;font-size: 16px;">Here’s the approximate peak-dose weig= ht loss across the modern GLP-1 field:</p><ul style=3D"margin-top: 0;paddin= g: 0;"><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p st= yle=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: = border-box;padding-left: 4px;font-size: 16px;margin: 0;"><strong>Retatrutid= e 12 mg</strong><span> (subq, weekly): ~28.7%</span></p></li><li style=3D"m= argin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,= 55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-le= ft: 4px;font-size: 16px;margin: 0;"><strong>Cagrisema</strong><span> (subq,= weekly): ~22.7%</span></p></li><li style=3D"margin: 8px 0 0 32px;mso-speci= al-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;marg= in-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margi= n: 0;"><strong>Tirzepatide 15 mg</strong><span> (subq, weekly): ~20.9%</spa= n></p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><= p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizi= ng: border-box;padding-left: 4px;font-size: 16px;margin: 0;"><strong>Semagl= utide 2.4 mg</strong><span> (subq, weekly): ~14.9%</span></p></li><li style= =3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rg= b(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;paddi= ng-left: 4px;font-size: 16px;margin: 0;"><strong>Orforglipron 36 mg</strong= ><span> (oral, daily): ~12.4%</span></p></li><li style=3D"margin: 8px 0 0 3= 2px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-heig= ht: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-siz= e: 16px;margin: 0;"><strong>Oral semaglutide 14 mg</strong><span>: ~5.3%</s= pan></p></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-= height: 26px;font-size: 16px;">Orforglipron sits at the bottom of the new-g= eneration efficacy ladder. Not by a little. By a lot. Let’s walk thro= ugh each comparison honestly.</p><h3 class=3D"header-anchor-post" style=3D"= position: relative;font-family: 'SF Pro Display',-apple-system-headline,sys= tem-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,s= ans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weigh= t: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antial= iased;-webkit-appearance: optimizelegibility;-moz-appearance: optimizelegib= ility;appearance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,= 55,55);line-height: 1.16em;font-size: 1.375em;">Versus Subq Semaglutide (We= govy/Ozempic)</h3><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-= height: 26px;font-size: 16px;">Subq semaglutide delivers roughly 14.9% weig= ht loss in non-diabetic obesity. Orforglipron delivers 12.4%. That’s = a 2.5 percentage point gap in favor of subq.</p><p style=3D"margin: 0 0 20p= x 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Orforglipron h= olds up reasonably well here. This is the closest comparison in the entire = field. But it still loses to the oldest subq GLP-1 in the modern class R= 12; and that’s with orforglipron at its highest tested dose against s= emaglutide at its standard dose.</p><p style=3D"margin: 0 0 20px 0;color: r= gb(54,55,55);line-height: 26px;font-size: 16px;">One caveat worth noting: a= recent indirect comparison (the ORION analysis) using OASIS-4 data suggest= ed that oral semaglutide at the newer 25 mg dose may actually outperform or= forglipron in non-diabetic populations. Indirect comparison, not head-to-he= ad, so take it with appropriate skepticism. But it’s worth watching.<= /p><h3 class=3D"header-anchor-post" style=3D"position: relative;font-family= : 'SF Pro Display',-apple-system-headline,system-ui,-apple-system,BlinkMacS= ystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji',= 'Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-font-smoothing= : antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appearance: opti= mizelegibility;-moz-appearance: optimizelegibility;appearance: optimizelegi= bility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;fon= t-size: 1.375em;">Versus Tirzepatide (Mounjaro/Zepbound)</h3><p style=3D"ma= rgin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">S= ubq tirzepatide at 15 mg delivers roughly 20.9% weight loss. Orforglipron 3= 6 mg delivers 12.4%. That’s an eight percentage point gap.</p><p styl= e=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 1= 6px;">Eight percentage points is enormous. On a 250-pound baseline, that= 217;s the difference between losing 31 pounds and losing 52 pounds. Tirzepa= tide is the current efficacy leader among FDA-approved options, and if some= one can tolerate subq administration and is seeking maximum results, there = is no serious comparison to be made with orforglipron.</p><h3 class=3D"head= er-anchor-post" style=3D"position: relative;font-family: 'SF Pro Display',-= apple-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI'= ,Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Se= goe UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-o= sx-font-smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz-= appearance: optimizelegibility;appearance: optimizelegibility;margin: 1em 0= 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.375em;">Ve= rsus Retatrutide (Triple Agonist)</h3><p style=3D"margin: 0 0 20px 0;color:= rgb(54,55,55);line-height: 26px;font-size: 16px;">This is where the gap be= comes absurd. Subq retatrutide at 12 mg delivered 28.7% weight loss at 68 w= eeks in TRIUMPH-4. Break that down further:</p><ul style=3D"margin-top: 0;p= adding: 0;"><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">= <p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-siz= ing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">58.6% of part= icipants on 12 mg achieved at least 25% weight loss</p></li><li style=3D"ma= rgin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,5= 5,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-lef= t: 4px;font-size: 16px;margin: 0;">39.4% achieved at least 30%</p></li><li = style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"colo= r: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;= padding-left: 4px;font-size: 16px;margin: 0;">23.7% achieved at least 35%</= p></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height= : 26px;font-size: 16px;">Orforglipron 36 mg: 12.4%.</p><p style=3D"margin: = 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Retatru= tide is in a different universe — roughly 2.3x the efficacy at the sa= me time horizon. It’s still investigational and won’t hit the m= arket until 2026 or 2027, but when it does, it’s going to reset expec= tations for what GLP-class therapy can achieve.</p><p style=3D"margin: 0 0 = 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">One thing w= orth flagging on the retatrutide side: a new dysesthesia signal emerged in = TRIUMPH-4 (abnormal skin sensations like tingling) that wasn’t seen i= n the Phase 2 data. Discontinuation at 12 mg hit 18.2%, notably higher than= with orforglipron or tirzepatide. Part of this was attributed to “pe= rceived excessive weight loss” in lower-BMI participants, which is it= s own interesting signal. Worth watching as more Phase 3 data reads out thr= ough 2026.</p><h3 class=3D"header-anchor-post" style=3D"position: relative;= font-family: 'SF Pro Display',-apple-system-headline,system-ui,-apple-syste= m,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Co= lor Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-webkit-fon= t-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webkit-appea= rance: optimizelegibility;-moz-appearance: optimizelegibility;appearance: o= ptimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line-height:= 1.16em;font-size: 1.375em;">Versus Cagrisema (Cagrilintide + Semaglutide)<= /h3><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;f= ont-size: 16px;">Novo Nordisk’s entry in the dual-agonist space combi= nes a GLP-1 (semaglutide) with an amylin analog (cagrilintide). Subq, once-= weekly.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height:= 26px;font-size: 16px;">Cagrisema delivered 22.7% weight loss in REDEFINE 1= under the full-adherence estimand. That roughly doubles orforglipron’= ;s efficacy.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-he= ight: 26px;font-size: 16px;">Worth noting: REDEFINE 4, the head-to-head aga= inst tirzepatide, failed to show noninferiority. So cagrisema doesn’t= displace tirz at the top of the efficacy hierarchy. But it absolutely demo= lishes orforglipron.</p><div style=3D"font-size: 16px;line-height: 26px;"><= hr style=3D"margin: 32px 0;padding: 0;height: 1px;background: rgb(0,0,0,.1)= ;border: none;"></div><h2 class=3D"header-anchor-post" style=3D"position: r= elative;font-family: 'SF Pro Display',-apple-system-headline,system-ui,-app= le-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'= Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font-weight: bold;-we= bkit-font-smoothing: antialiased;-moz-osx-font-smoothing: antialiased;-webk= it-appearance: optimizelegibility;-moz-appearance: optimizelegibility;appea= rance: optimizelegibility;margin: 1em 0 0.625em 0;color: rgb(54,55,55);line= -height: 1.16em;font-size: 1.625em;">So Who Is Orforglipron Actually For</h= 2><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;fon= t-size: 16px;">This is the real question, and the honest answer is narrower= than the marketing will suggest.</p><p style=3D"margin: 0 0 20px 0;color: = rgb(54,55,55);line-height: 26px;font-size: 16px;"><strong>It’s a legi= timate option for:</strong></p><p style=3D"margin: 0 0 20px 0;color: rgb(54= ,55,55);line-height: 26px;font-size: 16px;"><span>The single largest popula= tion is </span><strong>people who won’t use subq, period.</strong><sp= an> Needle aversion is real and prevalent. A significant portion of patient= s who would otherwise benefit from GLP-1 therapy refuse it outright because= of the self-administration requirement. For that population, getting 12% w= eight loss through a pill is infinitely better than getting 0% because they= won’t inject. This is not a small group.</span></p><p style=3D"margi= n: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size: 16px;">Beyo= nd that, orforglipron is reasonable for:</p><ul style=3D"margin-top: 0;padd= ing: 0;"><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p = style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing= : border-box;padding-left: 4px;font-size: 16px;margin: 0;">Early interventi= on or less extreme cases where 12-13% weight loss is clinically sufficient<= /p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p s= tyle=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing:= border-box;padding-left: 4px;font-size: 16px;margin: 0;">Step-down mainten= ance after subq therapy — the ATTAIN-MAINTAIN data supports this spec= ifically</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bull= et;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;bo= x-sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">Global a= ccess populations, particularly in regions where cold-chain storage and inj= ectable distribution are infrastructure problems. Small-molecule oral drugs= are dramatically easier to distribute than peptide injectables</p></li><li= style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"col= or: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box= ;padding-left: 4px;font-size: 16px;margin: 0;">Type 2 diabetes management w= hen oral dosing is strongly preferred — the ACHIEVE data is solid on = glycemic control</p></li></ul><p style=3D"margin: 0 0 20px 0;color: rgb(54,= 55,55);line-height: 26px;font-size: 16px;"><strong>It is not the right choi= ce for:</strong></p><ul style=3D"margin-top: 0;padding: 0;"><li style=3D"ma= rgin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,5= 5,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-lef= t: 4px;font-size: 16px;margin: 0;">Anyone who can tolerate subq administrat= ion and is seeking maximum weight loss</p></li><li style=3D"margin: 8px 0 0= 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-he= ight: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-s= ize: 16px;margin: 0;">Patients with severe obesity who genuinely need 20%+ = reduction to reach clinical targets</p></li><li style=3D"margin: 8px 0 0 32= px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-heigh= t: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size= : 16px;margin: 0;">Anyone choosing between orforglipron and tirzepatide, re= tatrutide, or cagrisema purely on efficacy</p></li></ul><div style=3D"font-= size: 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padding: 0;heigh= t: 1px;background: rgb(0,0,0,.1);border: none;"></div><h2 class=3D"header-a= nchor-post" style=3D"position: relative;font-family: 'SF Pro Display',-appl= e-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Rob= oto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe = UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-f= ont-smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz-appe= arance: optimizelegibility;appearance: optimizelegibility;margin: 1em 0 0.6= 25em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.625em;">What W= e Still Don’t Know</h2><p style=3D"margin: 0 0 20px 0;color: rgb(54,5= 5,55);line-height: 26px;font-size: 16px;">The Phase 3 package is robust, bu= t there are genuine unknowns:</p><ul style=3D"margin-top: 0;padding: 0;"><l= i style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"co= lor: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-bo= x;padding-left: 4px;font-size: 16px;margin: 0;">Long-term cardiovascular ou= tcomes data is still pending (the trial is ongoing)</p></li><li style=3D"ma= rgin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,5= 5,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-lef= t: 4px;font-size: 16px;margin: 0;">Real-world adherence outside controlled = trial settings</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format= : bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom= : 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">He= ad-to-head data versus tirzepatide (doesn’t exist and likely never wi= ll)</p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">= <p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-siz= ing: border-box;padding-left: 4px;font-size: 16px;margin: 0;">Head-to-head = versus subq semaglutide for obesity specifically (doesn’t exist)</p><= /li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style= =3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: bor= der-box;padding-left: 4px;font-size: 16px;margin: 0;">How efficacy holds pa= st 72 weeks — the known treatment horizon</p></li></ul><div style=3D"= font-size: 16px;line-height: 26px;"><hr style=3D"margin: 32px 0;padding: 0;= height: 1px;background: rgb(0,0,0,.1);border: none;"></div><h2 class=3D"hea= der-anchor-post" style=3D"position: relative;font-family: 'SF Pro Display',= -apple-system-headline,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI= ',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','S= egoe UI Symbol';font-weight: bold;-webkit-font-smoothing: antialiased;-moz-= osx-font-smoothing: antialiased;-webkit-appearance: optimizelegibility;-moz= -appearance: optimizelegibility;appearance: optimizelegibility;margin: 1em = 0 0.625em 0;color: rgb(54,55,55);line-height: 1.16em;font-size: 1.625em;">T= he Bottom Line</h2><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line= -height: 26px;font-size: 16px;">Orforglipron is not a gimmick. The science = is legitimate. The Phase 3 data is rigorous. It’s going to help a rea= l population that would never otherwise benefit from GLP-1 therapy. That is= genuinely valuable, and I don’t want any of the honest framing above= to obscure that point.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,= 55);line-height: 26px;font-size: 16px;">But let’s call it what it is.= Orforglipron is the entry-level modern GLP-1. It trades efficacy for oral = convenience. For people averse to subcutaneous administration, that tradeof= f makes sense and the oral option is better than nothing. For everyone else= , subq is going to outperform it — often by enormous margins.</p><p s= tyle=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-size= : 16px;">The marketing is going to frame this as “GLP-1s for everyone= =2E” The reality is it’s a=20= real option for a specific slice of th= e population. That slice is meaningful. It’s just not the whole marke= t.</p><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px= ;font-size: 16px;">If you’re comfortable with subq administration and= seeking maximum results, the tirzepatide, retatrutide, and cagrisema tier = is where the action is. If oral is the only pathway you’ll accept, or= forglipron is a genuine option — and a meaningfully better one than a= ny oral GLP-1 that came before it.</p><p style=3D"margin: 0 0 20px 0;color:= rgb(54,55,55);line-height: 26px;font-size: 16px;">Just don’t confuse= what it is with what it isn’t.</p><div style=3D"font-size: 16px;line= -height: 26px;"><hr style=3D"margin: 32px 0;padding: 0;height: 1px;backgrou= nd: rgb(0,0,0,.1);border: none;"></div><h2 class=3D"header-anchor-post" sty= le=3D"position: relative;font-family: 'SF Pro Display',-apple-system-headli= ne,system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,A= rial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';font= -weight: bold;-webkit-font-smoothing: antialiased;-moz-osx-font-smoothing: = antialiased;-webkit-appearance: optimizelegibility;-moz-appearance: optimiz= elegibility;appearance: optimizelegibility;margin: 1em 0 0.625em 0;color: r= gb(54,55,55);line-height: 1.16em;font-size: 1.625em;">Key References</h2><u= l style=3D"margin-top: 0;padding: 0;"><li style=3D"margin: 8px 0 0 32px;mso= -special-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26p= x;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px= ;margin: 0;"><span>Wharton S, et al. </span><em>Orforglipron for Obesity (A= TTAIN-1).</em><span> N Engl J Med. 2025;393(18). PMID 40960239</span></p></= li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style= =3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: bor= der-box;padding-left: 4px;font-size: 16px;margin: 0;"><span>Rosenstock J, e= t al. </span><em>Orforglipron in early type 2 diabetes (ACHIEVE-1).</em><sp= an> N Engl J Med. 2025;393:1065-1076</span></p></li><li style=3D"margin: 8p= x 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);li= ne-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;f= ont-size: 16px;margin: 0;"><span>Horn DB, et al. </span><em>Orforglipron in= T2D with obesity (ATTAIN-2).</em><span> Lancet. 2025</span></p></li><li st= yle=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color:= rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;pa= dding-left: 4px;font-size: 16px;margin: 0;"><span>Novo Nordisk. </span><em>= REDEFINE 1 — Cagrilintide plus Semaglutide (CagriSema).</em><span> N = Engl J Med. 2025</span></p></li><li style=3D"margin: 8px 0 0 32px;mso-speci= al-format: bullet;"><p style=3D"color: rgb(54,55,55);line-height: 26px;marg= in-bottom: 0;box-sizing: border-box;padding-left: 4px;font-size: 16px;margi= n: 0;"><span>Jastreboff AM, et al. </span><em>Tirzepatide Once Weekly for t= he Treatment of Obesity (SURMOUNT-1).</em><span> N Engl J Med. 2022</span><= /p></li><li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;"><p s= tyle=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizing:= border-box;padding-left: 4px;font-size: 16px;margin: 0;"><span>Wilding JPH= , et al. </span><em>Once-Weekly Semaglutide in Adults with Overweight or Ob= esity (STEP 1).</em><span> N Engl J Med. 2021</span></p></li><li style=3D"m= argin: 8px 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,= 55,55);line-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-le= ft: 4px;font-size: 16px;margin: 0;"><span>Jastreboff AM, et al. </span><em>= Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 T= rial.</em><span> N Engl J Med. 2023</span></p></li><li style=3D"margin: 8px= 0 0 32px;mso-special-format: bullet;"><p style=3D"color: rgb(54,55,55);lin= e-height: 26px;margin-bottom: 0;box-sizing: border-box;padding-left: 4px;fo= nt-size: 16px;margin: 0;">Eli Lilly press releases: TRIUMPH-4 (Dec 2025), A= TTAIN-MAINTAIN (Dec 2025), ATTAIN-2 (Aug 2025), ACHIEVE-3 (Sept 2025)</p></= li></ul><div style=3D"font-size: 16px;line-height: 26px;"><hr style=3D"marg= in: 32px 0;padding: 0;height: 1px;background: rgb(0,0,0,.1);border: none;">= </div><p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px= ;font-size: 16px;"><em>This post is for research and educational purposes o= nly. Orforglipron is not currently FDA approved. Any decisions about GLP-1 = therapy should involve qualified medical professionals.</em></p><div class= =3D"subscribe-widget is-signed-up" data-component-name=3D"SubscribeWidget" = style=3D"margin: 0 0 1em;direction: ltr;font-size: 16px;line-height: 26px;m= argin-bottom: 0;"><div class=3D"pencraft pc-reset button-wrapper" style=3D"= text-decoration: unset;list-style: none;font-size: 16px;line-height: 26px;t= ext-align: center;cursor: pointer;border-radius: 4px;"><a class=3D"button s= ubscribe-btn primary" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0c= HM6Ly9kZXJla3BydXNraS5zdWJzdGFjay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1= dG1fY2FtcGFpZ249ZW1haWwtY2hlY2tvdXQmbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2t= pLnN1YnN0YWNrLmNvbSUyRnAlMkZvcmZvcmdsaXByb24tZG9lcy1pdC13b3JrLXllcy1pcyZyPT= Rpd29lNiZ0b2tlbj1leUoxYzJWeVgybGtJam95TnpNMk1qSXpPVGdzSW1saGRDSTZNVGMzTmprM= 01ETXpPQ3dpWlhod0lqb3hOemM1TlRZeU16TTRMQ0pwYzNNaU9pSndkV0l0TXpNMk5UTTJOeUlz= SW5OMVlpSTZJbU5vWldOcmIzVjBJbjAuV1dVVHNHalVyeU1XYkN5bUE3enM4T1Y4dEZGa0VKRXF= EaFRueXJkd3JfQSIsInAiOjE5NTI3MjQzMSwicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNj= IyMzk4LCJpYXQiOjE3NzY5NzAzMzgsImV4cCI6MjA5MjU0NjMzOCwiaXNzIjoicHViLTAiLCJzd= WIiOiJsaW5rLXJlZGlyZWN0In0.Mua1SAxqMyMLXNwDukaKuhNgeDj5PDf9dSlwyTePO1o?&utm= _medium=3Demail&utm_source=3Dsubscribe-widget&utm_content=3D195272431" styl= e=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Rob= oto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe = UI Symbol';display: inline-block;box-sizing: border-box;cursor: pointer;bor= der: none;border-radius: 8px;font-size: 14px;line-height: 20px;font-weight:= 600;text-align: center;opacity: 1;outline: none;white-space: nowrap;text-d= ecoration: none !important;margin: 0 auto;background-color: #FF6719;color: = #ffffff !important;padding: 12px 20px;height: auto;"><span style=3D"color: = #ffffff;text-decoration: none;">Upgrade to paid</span></a></div></div></div= ></div><div class=3D"container-border" style=3D"margin: 32px 0 0;width: 100= %;box-sizing: border-box;border-top: 1px solid #e6e6e6;font-size: 16px;line= -height: 26px;"></div><div class=3D"post-cta typography markup" style=3D"--= image-offset-margin: -120px;text-align: initial;word-break: break-word;marg= in-bottom: 32px;margin: 32px 0;font-size: 16px;line-height: 26px;"><p style= =3D"color: rgb(54,55,55);margin: 0 auto 20px;text-align: center;width: 90%;= line-height: 26px;font-size: 16px;margin-top: 0;"><span class=3D"pencraft p= c-reset reset-IxiVJZ" translated=3D"" style=3D"list-style: none;color: unse= t;text-decoration: unset;margin: 0;">You're currently a free subscriber to = <a href=3D"https://substack.com/redirect/731979fd-6a7e-4a88-860b-3b66c44e38= d8?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs" sty= le=3D"color: #ff6719;text-decoration: none;">Research Radar</a>. For the fu= ll experience, <a href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6L= y9kZXJla3BydXNraS5zdWJzdGFjay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1dG1f= Y2FtcGFpZ249ZW1haWwtY2hlY2tvdXQmbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tpLnN= 1YnN0YWNrLmNvbSUyRnAlMkZvcmZvcmdsaXByb24tZG9lcy1pdC13b3JrLXllcy1pcyZyPTRpd2= 9lNiZ0b2tlbj1leUoxYzJWeVgybGtJam95TnpNMk1qSXpPVGdzSW1saGRDSTZNVGMzTmprM01ET= XpPQ3dpWlhod0lqb3hOemM1TlRZeU16TTRMQ0pwYzNNaU9pSndkV0l0TXpNMk5UTTJOeUlzSW5O= MVlpSTZJbU5vWldOcmIzVjBJbjAuV1dVVHNHalVyeU1XYkN5bUE3enM4T1Y4dEZGa0VKRXFEaFR= ueXJkd3JfQSIsInAiOjE5NTI3MjQzMSwicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMz= k4LCJpYXQiOjE3NzY5NzAzMzgsImV4cCI6MjA5MjU0NjMzOCwiaXNzIjoicHViLTAiLCJzdWIiO= iJsaW5rLXJlZGlyZWN0In0.Mua1SAxqMyMLXNwDukaKuhNgeDj5PDf9dSlwyTePO1o?&utm_sou= rce=3Dsubstack&utm_medium=3Demail&utm_content=3Dpostcta" style=3D"color: #f= f6719;text-decoration: none;">upgrade your subscription.</a></span></p><p c= lass=3D"cta-box" style=3D"color: rgb(54,55,55);margin: 0 auto 20px;width: 9= 0%;line-height: 26px;font-size: 16px;margin-bottom: 0;text-align: center;ma= rgin-left: auto;margin-right: auto;"><a class=3D"button primary" role=3D"bu= tton" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3Byd= XNraS5zdWJzdGFjay5jb20vc3Vic2NyaWJlP3V0bV9zb3VyY2U9cG9zdCZ1dG1fY2FtcGFpZ249= ZW1haWwtY2hlY2tvdXQmbmV4dD1odHRwcyUzQSUyRiUyRmRlcmVrcHJ1c2tpLnN1YnN0YWNrLmN= vbSUyRnAlMkZvcmZvcmdsaXByb24tZG9lcy1pdC13b3JrLXllcy1pcyZyPTRpd29lNiZ0b2tlbj= 1leUoxYzJWeVgybGtJam95TnpNMk1qSXpPVGdzSW1saGRDSTZNVGMzTmprM01ETXpPQ3dpWlhod= 0lqb3hOemM1TlRZeU16TTRMQ0pwYzNNaU9pSndkV0l0TXpNMk5UTTJOeUlzSW5OMVlpSTZJbU5v= WldOcmIzVjBJbjAuV1dVVHNHalVyeU1XYkN5bUE3enM4T1Y4dEZGa0VKRXFEaFRueXJkd3JfQSI= sInAiOjE5NTI3MjQzMSwicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMzk4LCJpYXQiOj= E3NzY5NzAzMzgsImV4cCI6MjA5MjU0NjMzOCwiaXNzIjoicHViLTAiLCJzdWIiOiJsaW5rLXJlZ= GlyZWN0In0.Mua1SAxqMyMLXNwDukaKuhNgeDj5PDf9dSlwyTePO1o?&utm_source=3Dsubsta= ck&utm_medium=3Demail&utm_content=3Dpostcta" style=3D"font-family: system-u= i,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-s= erif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';display: inline= -block;box-sizing: border-box;cursor: pointer;border: none;height: 40px;bor= der-radius: 8px;font-size: 14px;line-height: 20px;font-weight: 600;text-ali= gn: center;padding: 10px 20px;margin: 0;opacity: 1;outline: none;white-spac= e: nowrap;color: #ffffff !important;text-decoration: none !important;backgr= ound-color: #FF6719;">Upgrade to paid</a></p></div><table class=3D"email-uf= i-2-bottom" role=3D"presentation" width=3D"100%" border=3D"0" cellspacing= =3D"0" cellpadding=3D"0" style=3D"border-top: 1px solid rgb(0,0,0,.1);borde= r-bottom: 1px solid rgb(0,0,0,.1);min-width: 100%;"><tbody><tr height=3D"16= "><td height=3D"16" style=3D"font-size:0px;line-height:0;"> </td></tr>= <tr><td><table class=3D"email-ufi-2-row" role=3D"presentation" width=3D"100= %" border=3D"0" cellspacing=3D"0" cellpadding=3D"0" style=3D"border-bottom:= 1px solid rgb(0,0,0,.1);"><tbody><tr><td width=3D"95%"><table class=3D"ema= il-button-outline-wrapper-full-width" role=3D"presentation" width=3D"auto" = border=3D"0" cellspacing=3D"0" cellpadding=3D"0" style=3D"width: 95%;margin= : 0 auto;"><tbody><tr><td align=3D"center"><a class=3D"email-button-outline= full-width" href=3D"https://substack.com/app-link/post?publication_id=3D33= 65367&post_id=3D195272431&utm_source=3Dsubstack&utm_medium=3Demail&utm_cont= ent=3Dshare&utm_campaign=3Demail-share&action=3Dshare&triggerShare=3Dtrue&i= sFreemail=3Dtrue&r=3D4iwoe6&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3RfaWQ= iOjE5NTI3MjQzMSwiaWF0IjoxNzc2OTcwMzM4LCJleHAiOjE3Nzk1NjIzMzgsImlzcyI6InB1Yi= 0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.4bH2Idg-KfvdHXtYQwn-UDDtwJ8AghK1= X9l5yvGpu5Q" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFo= nt,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe = UI Emoji','Segoe UI Symbol';display: inline-block;font-weight: 500;border: = 1px solid rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;fon= t-size: 12px;line-height: 12px;padding: 9px 14px;text-decoration: none;colo= r: rgb(119,119,119);width: 100%;padding-left: 0;padding-right: 0;"><img cla= ss=3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_!rmYa!,w_36,c_sca= le,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Ficon= %2FLucideShare%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%2= 6strokeWidth%3D2" width=3D"18" height=3D"18" style=3D"margin-right: 8px;min= -width: 18px;min-height: 18px;border: none;vertical-align: middle;max-width= : 18px" alt=3D""><span class=3D"email-button-text" style=3D"vertical-align:= middle;">Share</span></a></td></tr></tbody></table></td></tr><tr height=3D= "16"><td height=3D"16" style=3D"font-size:0px;line-height:0;"> </td></= tr></tbody></table></td></tr><tr height=3D"16"><td height=3D"16" style=3D"f= ont-size:0px;line-height:0;"> </td></tr><tr><td><table role=3D"present= ation" width=3D"100%" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbo= dy><tr><td><table role=3D"presentation" width=3D"auto" border=3D"0" cellspa= cing=3D"0" cellpadding=3D"0" style=3D"margin:0 auto;"><tbody><tr><td style= =3D"vertical-align:middle;"><table role=3D"presentation" width=3D"auto" bor= der=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"cente= r"><a class=3D"email-button-outline" href=3D"https://substack.com/app-link/= post?publication_id=3D3365367&post_id=3D195272431&utm_source=3Dsubstack&isF= reemail=3Dtrue&submitLike=3Dtrue&token=3DeyJ1c2VyX2lkIjoyNzM2MjIzOTgsInBvc3= RfaWQiOjE5NTI3MjQzMSwicmVhY3Rpb24iOiLinaQiLCJpYXQiOjE3NzY5NzAzMzgsImV4cCI6M= Tc3OTU2MjMzOCwiaXNzIjoicHViLTMzNjUzNjciLCJzdWIiOiJyZWFjdGlvbiJ9.Ixx_vp2Kovk= nzVd5lllo6I8bGLqg_yOW4LO9GuH6XBY&utm_medium=3Demail&utm_campaign=3Demail-re= action&r=3D4iwoe6" style=3D"font-family: system-ui,-apple-system,BlinkMacSy= stemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','= Segoe UI Emoji','Segoe UI Symbol';display: inline-block;font-weight: 500;bo= rder: 1px solid rgb(0,0,0,.1);border-radius: 9999px;text-transform: upperca= se;font-size: 12px;line-height: 12px;padding: 9px 14px;text-decoration: non= e;color: rgb(119,119,119);"><img class=3D"icon" src=3D"https://substackcdn.= com/image/fetch/$s_!PeVs!,w_36,c_scale,f_png,q_auto:good,fl_progressive:ste= ep/https%3A%2F%2Fsubstack.com%2Ficon%2FLucideHeart%3Fv%3D4%26height%3D36%26= fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height= =3D"18" style=3D"margin-right: 8px;min-width: 18px;min-height: 18px;border:= none;vertical-align: middle;max-width: 18px" alt=3D""><span class=3D"email= -button-text" style=3D"vertical-align: middle;">Like</span></a></td></tr></= tbody></table></td><td width=3D"8" style=3D"min-width:8px;"></td><td style= =3D"vertical-align:middle;"><table role=3D"presentation" width=3D"auto" bor= der=3D"0" cellspacing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"cente= r"><a class=3D"email-button-outline" href=3D"https://substack.com/app-link/= post?publication_id=3D3365367&post_id=3D195272431&utm_source=3Dsubstack&utm= _medium=3Demail&isFreemail=3Dtrue&comments=3Dtrue&token=3DeyJ1c2VyX2lkIjoyN= zM2MjIzOTgsInBvc3RfaWQiOjE5NTI3MjQzMSwiaWF0IjoxNzc2OTcwMzM4LCJleHAiOjE3Nzk1= NjIzMzgsImlzcyI6InB1Yi0zMzY1MzY3Iiwic3ViIjoicG9zdC1yZWFjdGlvbiJ9.4bH2Idg-Kf= vdHXtYQwn-UDDtwJ8AghK1X9l5yvGpu5Q&r=3D4iwoe6&utm_campaign=3Demail-half-magi= c-comments&action=3Dpost-comment&utm_source=3Dsubstack&utm_medium=3Demail" = style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,'Segoe UI'= ,Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI Emoji','Se= goe UI Symbol';display: inline-block;font-weight: 500;border: 1px solid rgb= (0,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-size: 12px;= line-height: 12px;padding: 9px 14px;text-decoration: none;color: rgb(119,11= 9,119);"><img class=3D"icon" src=3D"https://substackcdn.com/image/fetch/$s_= !x1tS!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsu= bstack.com%2Ficon%2FLucideComments%3Fv%3D4%26height%3D36%26fill%3Dnone%26st= roke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"18" style=3D"m= argin-right: 8px;min-width: 18px;min-height: 18px;border: none;vertical-ali= gn: middle;max-width: 18px" alt=3D""><span class=3D"email-button-text" styl= e=3D"vertical-align: middle;">Comment</span></a></td></tr></tbody></table><= /td><td width=3D"8" style=3D"min-width:8px;"></td><td style=3D"vertical-ali= gn:middle;"><table role=3D"presentation" width=3D"auto" border=3D"0" cellsp= acing=3D"0" cellpadding=3D"0"><tbody><tr><td align=3D"center"><a class=3D"e= mail-button-outline" href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0cH= M6Ly9vcGVuLnN1YnN0YWNrLmNvbS9wdWIvZGVyZWtwcnVza2kvcC9vcmZvcmdsaXByb24tZG9lc= y1pdC13b3JrLXllcy1pcz91dG1fc291cmNlPXN1YnN0YWNrJnV0bV9tZWRpdW09ZW1haWwmdXRt= X2NhbXBhaWduPWVtYWlsLXJlc3RhY2stY29tbWVudCZhY3Rpb249cmVzdGFjay1jb21tZW50JnI= 9NGl3b2U2JnRva2VuPWV5SjFjMlZ5WDJsa0lqb3lOek0yTWpJek9UZ3NJbkJ2YzNSZmFXUWlPak= U1TlRJM01qUXpNU3dpYVdGMElqb3hOemMyT1Rjd016TTRMQ0psZUhBaU9qRTNOemsxTmpJek16Z= 3NJbWx6Y3lJNkluQjFZaTB6TXpZMU16WTNJaXdpYzNWaUlqb2ljRzl6ZEMxeVpXRmpkR2x2YmlK= OS40YkgySWRnLUtmdmRIWHRZUXduLVVERHR3SjhBZ2hLMVg5bDV5dkdwdTVRIiwicCI6MTk1Mjc= yNDMxLCJzIjozMzY1MzY3LCJmIjp0cnVlLCJ1IjoyNzM2MjIzOTgsImlhdCI6MTc3Njk3MDMzOC= wiZXhwIjoyMDkyNTQ2MzM4LCJpc3MiOiJwdWItMCIsInN1YiI6ImxpbmstcmVkaXJlY3QifQ.0J= UAvDSP9N8SoVGSeRUF5Ocp8Az_QzO1uVecwen9pNI?&utm_source=3Dsubstack&utm_medium= =3Demail" style=3D"font-family: system-ui,-apple-system,BlinkMacSystemFont,= 'Segoe UI',Roboto,Helvetica,Arial,sans-serif,'Apple Color Emoji','Segoe UI = Emoji','Segoe UI Symbol';display: inline-block;font-weight: 500;border: 1px= solid rgb(0,0,0,.1);border-radius: 9999px;text-transform: uppercase;font-s= ize: 12px;line-height: 12px;padding: 9px 14px;text-decoration: none;color: = rgb(119,119,119);"><img class=3D"icon" src=3D"https://substackcdn.com/image= /fetch/$s_!ubXF!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%= 3A%2F%2Fsubstack.com%2Ficon%2Fnotes__NoteRestackIcon%3Fv%3D4%26height%3D36%= 26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2%26strokeLinecap%3Dro= und%26strokeLinejoin%3Dround" width=3D"18" height=3D"18" alt=3D"" style=3D"= margin-right: 8px;min-width: 18px;min-height: 18px;max-width: 550px;border:= none !important;vertical-align: middle;"><span class=3D"email-button-text"= style=3D"vertical-align: middle;">Restack</span></a></td></tr></tbody></ta= ble></td></tr></tbody></table></td><td align=3D"right"><table role=3D"prese= ntation" width=3D"auto" border=3D"0" cellspacing=3D"0" cellpadding=3D"0"><t= body><tr></tr></tbody></table></td></tr></tbody></table></td></tr><tr heigh= t=3D"16"><td height=3D"16" style=3D"font-size:0px;line-height:0;"> </t= d></tr></tbody></table><div class=3D"footer footer-ZM59BM" style=3D"color: = rgb(119,119,119);text-align: center;font-size: 16px;line-height: 26px;paddi= ng: 24px0;"><div style=3D"font-size: 16px;line-height: 26px;padding-bottom:= 24px"><p class=3D"pencraft pc-reset color-secondary-ls1g8s size-12-mmZ61m = reset-IxiVJZ small meta-B2bqa5" style=3D"list-style: none;font-family: syst= em-ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sa= ns-serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';padding-bot= tom: 0;font-size: 12px;line-height: 16px;margin: 0;color: rgb(119,119,119);= text-decoration: unset;">© 2026 <span>Derek Pruski</span><br>548 Marke= t Street PMB 72296, San Francisco, CA 94104 <br><a href=3D"https://substack= =2Ecom/redirect/2/eyJlIjoiaHR0cHM6Ly9kZ= XJla3BydXNraS5zdWJzdGFjay5jb20vYWN0aW9= uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSWpveU56TTJNakl6T1Rnc0luQnZjM1= JmYVdRaU9qRTVOVEkzTWpRek1Td2lhV0YwSWpveE56YzJPVGN3TXpNNExDSmxlSEFpT2pFNE1EZ= zFNRFl6TXpnc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lpd2ljM1ZpSWpvaVpHbHpZV0pzWlY5= bGJXRnBiQ0o5LndOZ1FON2Q0c1MxVjFHWENkc2ZJRVVyZktValBqUWJVNGd5SUh4SDByT28iLCJ= wIjoxOTUyNzI0MzEsInMiOjMzNjUzNjcsImYiOnRydWUsInUiOjI3MzYyMjM5OCwiaWF0IjoxNz= c2OTcwMzM4LCJleHAiOjIwOTI1NDYzMzgsImlzcyI6InB1Yi0wIiwic3ViIjoibGluay1yZWRpc= mVjdCJ9.weLgFxEswzmC40eiFDorPw4rvIXfjyl9qA_vL6dj30w?" style=3D"color: #ff67= 19;text-decoration: none;"><span style=3D"color: rgb(119,119,119);text-deco= ration: underline;">Unsubscribe</span></a></p></div><p class=3D"footerSecti= on-EHR0jG small powered-by-substack" style=3D"padding: 0 24px;font-size: 12= px;line-height: 20px;margin: 0;color: rgb(119,119,119);font-family: system-= ui,-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Helvetica,Arial,sans-= serif,'Apple Color Emoji','Segoe UI Emoji','Segoe UI Symbol';padding-bottom= : 0;margin-top: 0;"><a href=3D"https://substack.com/redirect/2/eyJlIjoiaHR0= cHM6Ly9zdWJzdGFjay5jb20vc2lnbnVwP3V0bV9zb3VyY2U9c3Vic3RhY2smdXRtX21lZGl1bT1= lbWFpbCZ1dG1fY29udGVudD1mb290ZXImdXRtX2NhbXBhaWduPWF1dG9maWxsZWQtZm9vdGVyJm= ZyZWVTaWdudXBFbWFpbD10anBodWhzQGdtYWlsLmNvbSZyPTRpd29lNiIsInAiOjE5NTI3MjQzM= SwicyI6MzM2NTM2NywiZiI6dHJ1ZSwidSI6MjczNjIyMzk4LCJpYXQiOjE3NzY5NzAzMzgsImV4= cCI6MjA5MjU0NjMzOCwiaXNzIjoicHViLTAiLCJzdWIiOiJsaW5rLXJlZGlyZWN0In0.N-Qm1HD= Y6gVDY5TZMqH8j0Bq9xNnZDFp_YUI5czXkSo?" style=3D"color: #ff6719;text-decorat= ion: none;display: inline-block;margin: 0 4px;"><img src=3D"https://substac= kcdn.com/image/fetch/$s_!LkrL!,w_270,c_limit,f_auto,q_auto:good,fl_progress= ive:steep/https%3A%2F%2Fsubstack.com%2Fimg%2Femail%2Fpublish-button%402x.pn= g" srcset=3D"https://substackcdn.com/image/fetch/$s_!wgfj!,w_135,c_limit,f_= auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.com%2Fimg%2Fem= ail%2Fpublish-button.png, https://substackcdn.com/image/fetch/$s_!LkrL!,w_2= 70,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack.c= om%2Fimg%2Femail%2Fpublish-button%402x.png 2x, https://substackcdn.com/imag= e/fetch/$s_!KjtY!,w_405,c_limit,f_auto,q_auto:good,fl_progressive:steep/htt= ps%3A%2F%2Fsubstack.com%2Fimg%2Femail%2Fpublish-button%403x.png 3x" width= =3D"135" alt=3D"Start writing" height=3D"40" style=3D"max-width: 550px;bord= er: none !important;vertical-align: middle;"></a></p></div></div></td><td><= /td></tr></tbody></table><img src=3D"https://eotrx.substackcdn.com/o/94effa= 52cb9c5327/p.gif?token=3DeyJtIjoiPDIwMjYwNDIzMTg1MTI0LjMuMTI0ZWM5MzZjNTc2Yz= gwNkBtZy1kMS5zdWJzdGFjay5jb20-IiwidSI6MjczNjIyMzk4LCJyIjoidGpwaHVoc0BnbWFpb= C5jb20iLCJkIjoibWctZDEuc3Vic3RhY2suY29tIiwicCI6MTk1MjcyNDMxLCJ0IjoibmV3c2xl= dHRlciIsImEiOiJldmVyeW9uZSIsInMiOjMzNjUzNjcsImMiOiJwb3N0IiwiZiI6dHJ1ZSwicG9= zaXRpb24iOiJib3R0b20iLCJpYXQiOjE3NzY5NzAzMzgsImV4cCI6MTc3OTU2MjMzOCwiaXNzIj= oicHViLTAiLCJzdWIiOiJlbyJ9.l4gHMc48tsbF7FuKKWqFAaJTbN1RWytwR3iPrvnfopM" alt= =3D"" width=3D"1" height=3D"1" border=3D"0" style=3D"height:1px !important;= width:1px !important;border-width:0 !important;margin-top:0 !important;marg= in-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;p= adding-top:0 !important;padding-bottom:0 !important;padding-right:0 !import= ant;padding-left:0 !important;"/><img width=3D"1" height=3D"1" alt=3D"" src= =3D"https://email.mg-d1.substack.com/o/eJxM0M2uqyAUxfGnKbNrgI2gA57FIKxabhUN= Hz3x7U9sOzjTtZN_ftneVSx7Pu2xl8qCpXHmg9cMVhijR8OJBobNxXVakJBdRZhc_XNVYmQPqwN= 3BIIWUhv0g_JchEB0h-OGyLBoJZeaK0li6IVUHXVCKviRtO-N9gPXN8W35V8QXWlzqc4_O79vLJ= bpnvEm2Job2CWdXAsRycPihXzu6TvHYMXYSyMVic9SzwM24aesqBWZHW2e_L5tLcV6TkhuXhG-4= Tav0bsa93SFiHRP2rBs6__j0R7lpvhyMd6s0uawby4mG5DxPHIrz8jq54-tIF8JaUhLSePAXlb-= BgAA__8F5ndI"></body></html> --b737f41e539c0af1dc573c81921fd2fea2b817af5a3444513ab8dad61c6f--